ZA200210133B - Methods and compositions utilizing quinazolinones. - Google Patents
Methods and compositions utilizing quinazolinones. Download PDFInfo
- Publication number
- ZA200210133B ZA200210133B ZA200210133A ZA200210133A ZA200210133B ZA 200210133 B ZA200210133 B ZA 200210133B ZA 200210133 A ZA200210133 A ZA 200210133A ZA 200210133 A ZA200210133 A ZA 200210133A ZA 200210133 B ZA200210133 B ZA 200210133B
- Authority
- ZA
- South Africa
- Prior art keywords
- substituted
- alkyl
- chosen
- hydrogen
- aryl
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 58
- 239000000203 mixture Substances 0.000 title description 59
- AVRPFRMDMNDIDH-UHFFFAOYSA-N 1h-quinazolin-2-one Chemical class C1=CC=CC2=NC(O)=NC=C21 AVRPFRMDMNDIDH-UHFFFAOYSA-N 0.000 title description 33
- 125000000217 alkyl group Chemical group 0.000 claims description 308
- -1 substituted Chemical class 0.000 claims description 277
- 229910052739 hydrogen Inorganic materials 0.000 claims description 215
- 239000001257 hydrogen Substances 0.000 claims description 215
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 165
- 150000001875 compounds Chemical class 0.000 claims description 149
- 125000001072 heteroaryl group Chemical group 0.000 claims description 141
- 150000002431 hydrogen Chemical class 0.000 claims description 123
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims description 113
- 125000003118 aryl group Chemical group 0.000 claims description 104
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 90
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 84
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 84
- 125000003107 substituted aryl group Chemical group 0.000 claims description 80
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 76
- 125000003545 alkoxy group Chemical group 0.000 claims description 63
- 125000005843 halogen group Chemical group 0.000 claims description 57
- 108010063296 Kinesin Proteins 0.000 claims description 55
- 102000010638 Kinesin Human genes 0.000 claims description 55
- 206010028980 Neoplasm Diseases 0.000 claims description 55
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 52
- 230000000694 effects Effects 0.000 claims description 50
- 150000003839 salts Chemical class 0.000 claims description 47
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 41
- 230000027455 binding Effects 0.000 claims description 40
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 31
- 125000001624 naphthyl group Chemical group 0.000 claims description 25
- 125000003282 alkyl amino group Chemical group 0.000 claims description 24
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 23
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 23
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 22
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 22
- 201000011510 cancer Diseases 0.000 claims description 17
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 16
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 16
- 229910052736 halogen Inorganic materials 0.000 claims description 15
- 150000002367 halogens Chemical class 0.000 claims description 15
- 125000000623 heterocyclic group Chemical group 0.000 claims description 15
- 125000001153 fluoro group Chemical group F* 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 13
- 125000004414 alkyl thio group Chemical group 0.000 claims description 12
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 11
- 238000012216 screening Methods 0.000 claims description 11
- 125000003944 tolyl group Chemical group 0.000 claims description 11
- 125000005518 carboxamido group Chemical group 0.000 claims description 10
- 125000004181 carboxyalkyl group Chemical group 0.000 claims description 10
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 10
- 125000003386 piperidinyl group Chemical group 0.000 claims description 10
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 9
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 9
- 125000002883 imidazolyl group Chemical group 0.000 claims description 8
- 230000002062 proliferating effect Effects 0.000 claims description 8
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 8
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 7
- 239000012867 bioactive agent Substances 0.000 claims description 7
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 7
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 7
- 125000003709 fluoroalkyl group Chemical group 0.000 claims description 7
- 125000005422 alkyl sulfonamido group Chemical group 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 208000035475 disorder Diseases 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims description 5
- 208000006029 Cardiomegaly Diseases 0.000 claims description 5
- 125000004799 bromophenyl group Chemical group 0.000 claims description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 5
- 230000001413 cellular effect Effects 0.000 claims description 5
- 125000005805 dimethoxy phenyl group Chemical group 0.000 claims description 5
- 125000005059 halophenyl group Chemical group 0.000 claims description 5
- 206010020718 hyperplasia Diseases 0.000 claims description 5
- 125000002757 morpholinyl group Chemical group 0.000 claims description 5
- 208000037803 restenosis Diseases 0.000 claims description 5
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000004802 cyanophenyl group Chemical group 0.000 claims description 4
- RMSGQZDGSZOJMU-UHFFFAOYSA-N 1-butyl-2-phenylbenzene Chemical group CCCCC1=CC=CC=C1C1=CC=CC=C1 RMSGQZDGSZOJMU-UHFFFAOYSA-N 0.000 claims description 3
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 3
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 3
- 125000004188 dichlorophenyl group Chemical group 0.000 claims description 3
- 125000002541 furyl group Chemical group 0.000 claims description 3
- 125000001041 indolyl group Chemical group 0.000 claims description 3
- 125000006178 methyl benzyl group Chemical group 0.000 claims description 3
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 3
- 125000004076 pyridyl group Chemical group 0.000 claims description 3
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 3
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 claims description 2
- 125000002393 azetidinyl group Chemical group 0.000 claims description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 2
- 125000004803 chlorobenzyl group Chemical group 0.000 claims description 2
- 125000006202 diisopropylaminoethyl group Chemical group [H]C([H])([H])C([H])(N(C([H])([H])C([H])([H])*)C([H])(C([H])([H])[H])C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- 125000006222 dimethylaminomethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])* 0.000 claims description 2
- 125000006277 halobenzyl group Chemical group 0.000 claims description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 2
- 125000006301 indolyl methyl group Chemical group 0.000 claims description 2
- 125000004372 methylthioethyl group Chemical group [H]C([H])([H])SC([H])([H])C([H])([H])* 0.000 claims description 2
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 9
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 2
- 125000000590 4-methylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 2
- 125000006501 nitrophenyl group Chemical group 0.000 claims 2
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims 1
- 229910019567 Re Re Inorganic materials 0.000 claims 1
- MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 claims 1
- 125000004464 hydroxyphenyl group Chemical group 0.000 claims 1
- 125000006513 pyridinyl methyl group Chemical group 0.000 claims 1
- 125000006223 tetrahydrofuranylmethyl group Chemical group 0.000 claims 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 60
- 239000003795 chemical substances by application Substances 0.000 description 56
- 210000004027 cell Anatomy 0.000 description 51
- 230000000394 mitotic effect Effects 0.000 description 49
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 41
- 102000029749 Microtubule Human genes 0.000 description 23
- 108091022875 Microtubule Proteins 0.000 description 23
- 210000004688 microtubule Anatomy 0.000 description 23
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 22
- 238000003556 assay Methods 0.000 description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
- 230000004663 cell proliferation Effects 0.000 description 19
- 239000000243 solution Substances 0.000 description 19
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 108090000623 proteins and genes Proteins 0.000 description 18
- 235000018102 proteins Nutrition 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 17
- 230000015572 biosynthetic process Effects 0.000 description 16
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 15
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 15
- 239000003112 inhibitor Substances 0.000 description 14
- 230000005764 inhibitory process Effects 0.000 description 14
- 238000003786 synthesis reaction Methods 0.000 description 13
- 239000003153 chemical reaction reagent Substances 0.000 description 12
- 238000011282 treatment Methods 0.000 description 12
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 11
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 11
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 230000011278 mitosis Effects 0.000 description 10
- 239000011347 resin Substances 0.000 description 10
- 229920005989 resin Polymers 0.000 description 10
- 108091006112 ATPases Proteins 0.000 description 9
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 239000008194 pharmaceutical composition Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 230000020347 spindle assembly Effects 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 8
- 201000009030 Carcinoma Diseases 0.000 description 8
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 208000009956 adenocarcinoma Diseases 0.000 description 8
- 229940000406 drug candidate Drugs 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 206010025323 Lymphomas Diseases 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 206010039491 Sarcoma Diseases 0.000 description 7
- 150000001412 amines Chemical class 0.000 description 7
- 125000000753 cycloalkyl group Chemical group 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
- 101001008953 Homo sapiens Kinesin-like protein KIF11 Proteins 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 229960000583 acetic acid Drugs 0.000 description 6
- 238000007792 addition Methods 0.000 description 6
- 125000002947 alkylene group Chemical group 0.000 description 6
- 230000022131 cell cycle Effects 0.000 description 6
- 238000009826 distribution Methods 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 125000001424 substituent group Chemical group 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- MNNNFJRLDBVJEZ-UHFFFAOYSA-N 3-benzyl-2-propylquinazolin-4-one Chemical compound CCCC1=NC2=CC=CC=C2C(=O)N1CC1=CC=CC=C1 MNNNFJRLDBVJEZ-UHFFFAOYSA-N 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 229930012538 Paclitaxel Natural products 0.000 description 5
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 230000010261 cell growth Effects 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 238000004821 distillation Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 125000005842 heteroatom Chemical group 0.000 description 5
- 102000055595 human KIF11 Human genes 0.000 description 5
- 230000007062 hydrolysis Effects 0.000 description 5
- 238000006460 hydrolysis reaction Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 229960001592 paclitaxel Drugs 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 206010041823 squamous cell carcinoma Diseases 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 5
- 230000004614 tumor growth Effects 0.000 description 5
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 4
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 4
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 206010024612 Lipoma Diseases 0.000 description 4
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 4
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 239000003080 antimitotic agent Substances 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 230000025084 cell cycle arrest Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 229940126214 compound 3 Drugs 0.000 description 4
- 229940125898 compound 5 Drugs 0.000 description 4
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 4
- 230000036244 malformation Effects 0.000 description 4
- 230000036456 mitotic arrest Effects 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 150000003246 quinazolines Chemical class 0.000 description 4
- 229940124530 sulfonamide Drugs 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 230000004580 weight loss Effects 0.000 description 4
- HTWMTDKMOSSPMU-UHFFFAOYSA-N 1,2-benzoxazin-4-one Chemical compound C1=CC=C2C(=O)C=NOC2=C1 HTWMTDKMOSSPMU-UHFFFAOYSA-N 0.000 description 3
- QMNUDYFKZYBWQX-UHFFFAOYSA-N 1H-quinazolin-4-one Chemical class C1=CC=C2C(=O)N=CNC2=C1 QMNUDYFKZYBWQX-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 229940123237 Taxane Drugs 0.000 description 3
- 206010043276 Teratoma Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940125782 compound 2 Drugs 0.000 description 3
- 238000006073 displacement reaction Methods 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 206010016629 fibroma Diseases 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 201000011066 hemangioma Diseases 0.000 description 3
- FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 description 3
- 230000000147 hypnotic effect Effects 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 208000026278 immune system disease Diseases 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 201000008968 osteosarcoma Diseases 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 238000007423 screening assay Methods 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 150000003456 sulfonamides Chemical class 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 150000003672 ureas Chemical class 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 description 2
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- YLRBJYMANQKEAW-UHFFFAOYSA-N 1-bromo-4-(bromomethyl)benzene Chemical compound BrCC1=CC=C(Br)C=C1 YLRBJYMANQKEAW-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- GHMIPQKBDZGKRJ-UHFFFAOYSA-N 3-benzyl-2-(1-bromopropyl)quinazolin-4-one Chemical compound CCC(Br)C1=NC2=CC=CC=C2C(=O)N1CC1=CC=CC=C1 GHMIPQKBDZGKRJ-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- APRZHQXAAWPYHS-UHFFFAOYSA-N 4-[5-[3-(carboxymethoxy)phenyl]-3-(4,5-dimethyl-1,3-thiazol-2-yl)tetrazol-3-ium-2-yl]benzenesulfonate Chemical compound S1C(C)=C(C)N=C1[N+]1=NC(C=2C=C(OCC(O)=O)C=CC=2)=NN1C1=CC=C(S([O-])(=O)=O)C=C1 APRZHQXAAWPYHS-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 201000003076 Angiosarcoma Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- GKQLYSROISKDLL-UHFFFAOYSA-N EEDQ Chemical compound C1=CC=C2N(C(=O)OCC)C(OCC)C=CC2=C1 GKQLYSROISKDLL-UHFFFAOYSA-N 0.000 description 2
- 241001635598 Enicostema Species 0.000 description 2
- 201000008808 Fibrosarcoma Diseases 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 208000032612 Glial tumor Diseases 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 208000002927 Hamartoma Diseases 0.000 description 2
- 208000001258 Hemangiosarcoma Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 208000018142 Leiomyosarcoma Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- JEYCTXHKTXCGPB-UHFFFAOYSA-N Methaqualone Chemical compound CC1=CC=CC=C1N1C(=O)C2=CC=CC=C2N=C1C JEYCTXHKTXCGPB-UHFFFAOYSA-N 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- 206010027626 Milia Diseases 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- LFTLOKWAGJYHHR-UHFFFAOYSA-N N-methylmorpholine N-oxide Chemical compound CN1(=O)CCOCC1 LFTLOKWAGJYHHR-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 2
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 description 2
- 229940122803 Vinca alkaloid Drugs 0.000 description 2
- 208000008383 Wilms tumor Diseases 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 230000000078 anti-malarial effect Effects 0.000 description 2
- 239000002518 antifoaming agent Substances 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000004305 biphenyl Substances 0.000 description 2
- 235000010290 biphenyl Nutrition 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 2
- 235000013877 carbamide Nutrition 0.000 description 2
- 208000002458 carcinoid tumor Diseases 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 238000001516 cell proliferation assay Methods 0.000 description 2
- 210000003850 cellular structure Anatomy 0.000 description 2
- 208000019065 cervical carcinoma Diseases 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 229960001270 d- tartaric acid Drugs 0.000 description 2
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 238000003821 enantio-separation Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 239000002532 enzyme inhibitor Substances 0.000 description 2
- 229940125532 enzyme inhibitor Drugs 0.000 description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 2
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 229940107698 malachite green Drugs 0.000 description 2
- FDZZZRQASAIRJF-UHFFFAOYSA-M malachite green Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1C(C=1C=CC=CC=1)=C1C=CC(=[N+](C)C)C=C1 FDZZZRQASAIRJF-UHFFFAOYSA-M 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000021121 meiosis Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 206010027191 meningioma Diseases 0.000 description 2
- 229960002803 methaqualone Drugs 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 230000008035 nerve activity Effects 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- ZDYVRSLAEXCVBX-UHFFFAOYSA-N pyridinium p-toluenesulfonate Chemical compound C1=CC=[NH+]C=C1.CC1=CC=C(S([O-])(=O)=O)C=C1 ZDYVRSLAEXCVBX-UHFFFAOYSA-N 0.000 description 2
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 229960001367 tartaric acid Drugs 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 150000003536 tetrazoles Chemical class 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229930192474 thiophene Natural products 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- BSVHTRRLCAVQCZ-JDEXMCKMSA-N (2s)-1-[(2s)-1-[(2s)-1-[(2s)-1-[(2s)-1-[(2s)-1-[(2s)-2-[[(2s)-1-[(2s)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-carboxypropanoyl]pyrrolidine-2-carbonyl]amino]propanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]pyrro Chemical compound C([C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(O)=O)C1=CC=C(O)C=C1 BSVHTRRLCAVQCZ-JDEXMCKMSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-benzodioxole Chemical compound C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 description 1
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- XBNGYFFABRKICK-UHFFFAOYSA-N 2,3,4,5,6-pentafluorophenol Chemical compound OC1=C(F)C(F)=C(F)C(F)=C1F XBNGYFFABRKICK-UHFFFAOYSA-N 0.000 description 1
- IMSODMZESSGVBE-UHFFFAOYSA-N 2-Oxazoline Chemical compound C1CN=CO1 IMSODMZESSGVBE-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical group OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 1
- XMTQQYYKAHVGBJ-UHFFFAOYSA-N 3-(3,4-DICHLOROPHENYL)-1,1-DIMETHYLUREA Chemical compound CN(C)C(=O)NC1=CC=C(Cl)C(Cl)=C1 XMTQQYYKAHVGBJ-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- QMAHVAFURJBOFV-UHFFFAOYSA-N 4-(bromomethyl)-3-nitrobenzoic acid Chemical group OC(=O)C1=CC=C(CBr)C([N+]([O-])=O)=C1 QMAHVAFURJBOFV-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- 125000006618 5- to 10-membered aromatic heterocyclic group Chemical group 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 1
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 206010001233 Adenoma benign Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 206010073106 Bone giant cell tumour malignant Diseases 0.000 description 1
- 240000005589 Calophyllum inophyllum Species 0.000 description 1
- 208000009458 Carcinoma in Situ Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 206010008263 Cervical dysplasia Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 101800001982 Cholecystokinin Proteins 0.000 description 1
- 102100025841 Cholecystokinin Human genes 0.000 description 1
- 201000005262 Chondroma Diseases 0.000 description 1
- 201000009047 Chordoma Diseases 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- XXAXVMUWHZHZMJ-UHFFFAOYSA-N Chymopapain Chemical compound OC1=CC(S(O)(=O)=O)=CC(S(O)(=O)=O)=C1O XXAXVMUWHZHZMJ-UHFFFAOYSA-N 0.000 description 1
- 108090001069 Chymopapain Proteins 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 206010048832 Colon adenoma Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000183583 Cymo Species 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- 108700011813 Drosophila Klp61F Proteins 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 208000007033 Dysgerminoma Diseases 0.000 description 1
- 208000000471 Dysplastic Nevus Syndrome Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 201000009051 Embryonal Carcinoma Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 208000007659 Fibroadenoma Diseases 0.000 description 1
- 206010053717 Fibrous histiocytoma Diseases 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 208000000527 Germinoma Diseases 0.000 description 1
- 208000007569 Giant Cell Tumors Diseases 0.000 description 1
- 201000005409 Gliomatosis cerebri Diseases 0.000 description 1
- 206010018404 Glucagonoma Diseases 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 229910004373 HOAc Inorganic materials 0.000 description 1
- 206010019629 Hepatic adenoma Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001027192 Homo sapiens Kelch-like protein 41 Proteins 0.000 description 1
- 101000973200 Homo sapiens Nuclear factor 1 C-type Proteins 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 208000005045 Interdigitating dendritic cell sarcoma Diseases 0.000 description 1
- 102100037644 Kelch-like protein 41 Human genes 0.000 description 1
- 208000002260 Keloid Diseases 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 201000004462 Leydig Cell Tumor Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 208000002404 Liver Cell Adenoma Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 208000014767 Myeloproliferative disease Diseases 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 201000004404 Neurofibroma Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 102100022162 Nuclear factor 1 C-type Human genes 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 201000010133 Oligodendroglioma Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 208000000035 Osteochondroma Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 208000027067 Paget disease of bone Diseases 0.000 description 1
- 101100272976 Panax ginseng CYP716A53v2 gene Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010077495 Peptide oostatic hormone Proteins 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- 208000007641 Pinealoma Diseases 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 102000013009 Pyruvate Kinase Human genes 0.000 description 1
- 108020005115 Pyruvate Kinase Proteins 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 101000973172 Sus scrofa Nuclear factor 1 Proteins 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 208000009311 VIPoma Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 206010048214 Xanthoma Diseases 0.000 description 1
- 206010048215 Xanthomatosis Diseases 0.000 description 1
- 241000269370 Xenopus <genus> Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012042 active reagent Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 150000001266 acyl halides Chemical class 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 208000002718 adenomatoid tumor Diseases 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 125000005530 alkylenedioxy group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000031016 anaphase Effects 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 229940040526 anhydrous sodium acetate Drugs 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002927 anti-mitotic effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 125000005135 aryl sulfinyl group Chemical group 0.000 description 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 1
- 125000005110 aryl thio group Chemical group 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 208000001119 benign fibrous histiocytoma Diseases 0.000 description 1
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
- BNBQRQQYDMDJAH-UHFFFAOYSA-N benzodioxan Chemical compound C1=CC=C2OCCOC2=C1 BNBQRQQYDMDJAH-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 208000016738 bone Paget disease Diseases 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 201000009480 botryoid rhabdomyosarcoma Diseases 0.000 description 1
- 201000003149 breast fibroadenoma Diseases 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
- 201000002143 bronchus adenoma Diseases 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- DVECBJCOGJRVPX-UHFFFAOYSA-N butyryl chloride Chemical compound CCCC(Cl)=O DVECBJCOGJRVPX-UHFFFAOYSA-N 0.000 description 1
- 230000004611 cancer cell death Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 239000012069 chiral reagent Substances 0.000 description 1
- 125000000068 chlorophenyl group Chemical group 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 229940107137 cholecystokinin Drugs 0.000 description 1
- 201000005217 chondroblastoma Diseases 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 208000009060 clear cell adenocarcinoma Diseases 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 201000010305 cutaneous fibrous histiocytoma Diseases 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 125000002946 cyanobenzyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- GYOZYWVXFNDGLU-XLPZGREQSA-N dTMP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)C1 GYOZYWVXFNDGLU-XLPZGREQSA-N 0.000 description 1
- JSRLJPSBLDHEIO-SHYZEUOFSA-N dUMP Chemical compound O1[C@H](COP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 JSRLJPSBLDHEIO-SHYZEUOFSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
- 125000004982 dihaloalkyl group Chemical group 0.000 description 1
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 230000026058 directional locomotion Effects 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 238000002337 electrophoretic mobility shift assay Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 201000009409 embryonal rhabdomyosarcoma Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 238000001030 gas--liquid chromatography Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000015419 gastrin-producing neuroendocrine tumor Diseases 0.000 description 1
- 201000000052 gastrinoma Diseases 0.000 description 1
- 201000003115 germ cell cancer Diseases 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 208000006359 hepatoblastoma Diseases 0.000 description 1
- 201000002735 hepatocellular adenoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 125000006289 hydroxybenzyl group Chemical group 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 201000004933 in situ carcinoma Diseases 0.000 description 1
- 238000012750 in vivo screening Methods 0.000 description 1
- 230000010661 induction of programmed cell death Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229910052816 inorganic phosphate Inorganic materials 0.000 description 1
- 206010022498 insulinoma Diseases 0.000 description 1
- 210000002570 interstitial cell Anatomy 0.000 description 1
- 230000010189 intracellular transport Effects 0.000 description 1
- 201000010985 invasive ductal carcinoma Diseases 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 210000001117 keloid Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000022013 kidney Wilms tumor Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- FEWJPZIEWOKRBE-LWMBPPNESA-N levotartaric acid Chemical compound OC(=O)[C@@H](O)[C@H](O)C(O)=O FEWJPZIEWOKRBE-LWMBPPNESA-N 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 229940002712 malachite green oxalate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 201000004593 malignant giant cell tumor Diseases 0.000 description 1
- 201000000289 malignant teratoma Diseases 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- HRDXJKGNWSUIBT-UHFFFAOYSA-N methoxybenzene Chemical group [CH2]OC1=CC=CC=C1 HRDXJKGNWSUIBT-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000008880 microtubule cytoskeleton organization Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 208000010492 mucinous cystadenocarcinoma Diseases 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 208000009091 myxoma Diseases 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000007538 neurilemmoma Diseases 0.000 description 1
- 201000004662 neurofibroma of spinal cord Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 208000004649 neutrophil actin dysfunction Diseases 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 208000003388 osteoid osteoma Diseases 0.000 description 1
- 208000008798 osteoma Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 208000021255 pancreatic insulinoma Diseases 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- IZUPBVBPLAPZRR-UHFFFAOYSA-N pentachloro-phenol Natural products OC1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1Cl IZUPBVBPLAPZRR-UHFFFAOYSA-N 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 208000027232 peripheral nervous system disease Diseases 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 238000003566 phosphorylation assay Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 208000024724 pineal body neoplasm Diseases 0.000 description 1
- 201000004123 pineal gland cancer Diseases 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- SOSDSEAIODNVPX-UHFFFAOYSA-M potassium;1-carboxyethenyl hydrogen phosphate Chemical compound [K+].OC(=O)C(=C)OP(O)([O-])=O SOSDSEAIODNVPX-UHFFFAOYSA-M 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000000506 psychotropic effect Effects 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 229930002339 quinazoline alkaloid Natural products 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 208000029922 reticulum cell sarcoma Diseases 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 229910052702 rhenium Inorganic materials 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 206010039667 schwannoma Diseases 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 208000004548 serous cystadenocarcinoma Diseases 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 235000015393 sodium molybdate Nutrition 0.000 description 1
- 239000011684 sodium molybdate Substances 0.000 description 1
- TVXXNOYZHKPKGW-UHFFFAOYSA-N sodium molybdate (anhydrous) Chemical compound [Na+].[Na+].[O-][Mo]([O-])(=O)=O TVXXNOYZHKPKGW-UHFFFAOYSA-N 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 230000012391 spindle elongation Effects 0.000 description 1
- 230000020745 spindle pole body separation Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000010408 sweeping Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 1
- 208000001608 teratocarcinoma Diseases 0.000 description 1
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 125000001302 tertiary amino group Chemical group 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- XFNJVJPLKCPIBV-UHFFFAOYSA-N trimethylenediamine Natural products NCCCN XFNJVJPLKCPIBV-UHFFFAOYSA-N 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 208000022271 tubular adenoma Diseases 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 108010002164 tyrosine receptor Proteins 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 208000009540 villous adenoma Diseases 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Description
o 5
METHODS AND COMPOSITIONS UTILIZING QUINAZOLINONES
This invention relates to quinazolinone derivatives, which are inhibitors of the mitotic kinesin KSP and are useful in the treatment of cellular proliferative diseases, for example cancer, hyperplasia, restenosis, cardiac hypertrophy, immune disorders and inflammation.
Interest in the medicinal chemistry of quinazoline derivatives was stimulated in the, carly 1950's with the elucidation of the structure of a quinazoline alkaloid, 3-{8-keto- gamma-(3-hydroxy-2-piperidyl)-propyl]-4-quinazolone, from an Asian plant knowr! for its antimalarial properties. In a quest to find additional antimalarial ageats, various substituted quinazolines have been synthesized. Of particular import was the synthesis of the derivative 2-methyi-3-0-tolyl-4-(3H)-quinazolinone. This compound, known by the name methaqualone, though ineffective against protozoa, was found to bea potent hypnotic.
Since the introduction of methaqualone and its discovery as a hypnotic, the : pharmacological activity of quinazolinones and related compounds has been investigated. Quinazolinones and derivatives thereof are now known to have a wide variety of biological properties including hypnotic, sedative, analgesic, anticonvulsant, antitussive and anti-inflammatory activities.
Quinazolinone derivatives for which specific biological uses have been described include U.S. Patent No. 5,147,875 describing 2-(substituted phenyl)-4-oxo quinazolines with bronchodilator activity. U.S. Patent Nos. 3,723,432, 3,740,442, and 3,925,548 describe a class of 1 -substituted-4-aryl-2(1 H)-quinazolinone derivatives useful as anti-inflammatory agents. European patent publication EP 0 056 637 Bl claims a class of 4(3H)-quinazolinone derivatives for the treatment of hypertension.
European patent publication EP 0 884 319 Al describes pharmaceutical compositions of quinazolin-4-one derivatives used to treat nourodegencrative, psychotropic, and drug and alcohol induced central and peripheral nervous system disorders.
Quinazolinones are among a growing number of therapeutic agents used to treat cell proliferative disorders, including cancer. For example, PCT WO 96/06616 describes a pharmaceutical composition containing a quinazolinone derivative to inhibit vascular smooth cell proliferation. PCT WO 96/19224 uses this same quinazolinone derivative to inhibit mesengial cell proliferation. U.S. Patent Nos. 4,981,856, 5,081,124 and 5,280,027 describe the use of quinazolinone derivatives to inhibit thymidylaté synthase, the enzyme that catalyzes the methylation of deoxyuridine monophosphate to produce thymidine monophosphate which is required for DNA : synthesis. U.S. Patent Nos. 5,747,498 and 5,773,476 describe quinazolinone derivatives used to treat cancers characterized by over-activity or inappropriate activity of tyrosine receptor kinases. U.S. Patent No. 5,037,829 claims (1H-azol-1-- ylmethyl) substituted quinazoline compositions to treat carcinomas which occur in epithelial cells, PCT WO 98/34613 describes a composition containing a quinazolinone derivative useful for attenuating neovascularization and for treating malignancies. U.S. Patent 5,187,167 describes pharmaceutical compositions comprising quinazolin-4-one derivatives which possess anti-tumor activity.
Other therapeutic agents used to treat cancer include the taxanes and vinca alkaloids.
Taxanes and vinca alkaloids act on microtubules, which are present in a variety of cellular structures. Microtubules are the primary structural element of the mitotic spindle. The mitotic spindle is responsible for distribution of replicate copies of the genome to each of the two daughter cells that result from cell division. It is presumed that disruption of the mitotic spindle by these drugs results in inhibition of cancer cell division, and induction of cancer cell death. However, microtubules form other types of cellular structures, including tracks for intracellular transport in nerve processes.
Because these agents do not specifically target mitotic spindles, they have side effects that limit their usefulness.
Improvements in the specificity of agents used to treat cancer is of considerable interest because of the therapeutic benefits which would be realized if the side effects associated with the administration of these agents could be reduced. Traditionally, dramatic improvements in the treatment of cancer are associated with identification of therapeutic agents acting through novel mechanisms, Examples of this include not only the taxanes, but also the camptothecin class of topoisomerase I inhibitors. From both of these perspectives, mitotic kinesins are attractive targets for new anti-cancer agents.
Mitotic kinesins are enzymes essential for assembly and function of the mitotic spindle, but are not generally part of other microtubule structures, such as in nerve processes. Mitotic kinesins play essential roles during all phases of mitosis. These enzymes are "molecular motors" that transform energy released by hydrolysis of ATP into mechanical force which drives the directional movement of cellular cargoes along microtubules. The catalytic domain sufficient for this task is a compact structure of approximately 340 amino acids. During mitosis, kinesins organize microtubules into the bipolar structure that is the mitotic spindle. Kinesins mediate movement of : chromosomes along spindle microtubules, as well as structural changes in the mitotic spindle associated with specific phases of mitosis. Experimental perturbation of mitotic kinesin function causes malformation or dysfunction of the mitotic spindle, frequently resulting in cell cycle arrest and cell death.
Among the mitotic kinesins that have been identified is KSP. KSP belongs to an evolutionarily conserved kinesin subfamily of plus end-directed microtubule motors that assemble into bipolar homotetramers consisting of antiparallel homodimers.
During mitosis KSP associates with microtubules of the mitotic spindle. . 20 Microinjection of antibodies directed against KSP into human cells prevents spindle pole separation during prometaphase, giving rise to monopolar spindles and causing mitotic arrest and induction of programmed cell death. KSP and related kinesins in other, non-human, organisms, bundle antiparallel microtubules and slide them relative 0 one another, thus forcing the two spindle poles spart. KSP may also mediate in anaphase B spindle elongation and focussing of microtubules at the spindle pole.
Human KSP (also termed HsEgS5) has been described [Blangy, et al., Cell, 83:1159-69 (1995); Whitehead, et al, Arthritis Rheum., 39:1635-42 (1996); Galgio etal, J. Cell
Biol., 135:339-414 (1996); Blangy, et al., J Biol. Chem., 272:19418-24 (1997);
Blangy, ct al, Cell Motil Cytoskeleton, 40:174-82 (1998); Whitehead and Rattner, J.
Cell Sci., 111:2551-61 (1998); Kaiser, et al, JBC 274:18925-31 (1999); GenBank accession numbers: X85137, NM004523 and U37426), and a fragment of the KSP
38 ers forts k gene (TRIPS) bas been described [Lee, et al., Mol Endocrinol., 9:243-54 (1995);
GenBank accession number 140372]. Xenopus KSP homologs (Eg5), as well as
Drosophila KLP61 F/KRP1 30 have been reported.
Mitotic kinesins are attractive targets for the discovery and development of novel
S mitotic chemotherapeutics. Accordingly, it is an object of the present invention to provide methods and compositions useful in the inhibition of KSP, a mitotic kinesin.
In accordance with the objects outlined above, the present invention provides : compositions and methods that can be used to treat diseases of proliferating cells. The 10 compositions are KSP inhibitors, particularly human KSP inhibitors.
In one aspect, the invention relates to methods for treating cellular proliferative for treating disord iated with KSP kinesin activity, and for inhibit
KSP kinesin, The methods employ compounds chosen from the group consisting of: 0 Re 0 Re
AN Re Ph Re “| “
SNP CN(PZN
N Ry N Ry 0, N Re N
Y Nr, d Ng,
Re Ry 0 Re
Ry Re o Re
Nn
Re Ry Re
Ry" Nn Sy
N Ry Ra
Ry xn
N Re N Ry so” aS
N Re
L and nw’ Sr wherein:
R, is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, and substituted alkylheteroaryl;
Rand Ry’ are independently chosen from hydrogen, alkyl, oxaalkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, and substituted alkylheteroaryl; or Ra and Ry’ taken together form a 3- to 7-membered ring;
Ry is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, : substituted alkylheteroaryl, oxaalkyl, oxaalkylaryl, substituted oxaalkylaryl, oxaalkyl heteroaryl, substituted oxaalkylheteroaryl, R;5O- and R;s-NH-;
Ry: is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyiheteroaryl and Rs-NH-;
Ry is chosen from alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, and substituted alkylheteroaryl;
Ry is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, gubstituted alkylheteroaryl, and Ryg-alkylene-;
Rs, Rg R7 and Ry are independently chosen from hydrogen, alkyl, alkoxy, halogen, fluoroalkyl, nitro, cyano, dialkylamino, alkylsulfonyl, alkyisulfonamido, sulfonamidoalkyl, sulfonamidoaryl, alkylthio, carboxyalkyl, carboxamido, aminocarborryl, aryl and heretoaryl;
Ris is chosen from alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, and substituted ~~ alkylheteroaryl;
Ry is chosen from alkoxy, amino, alkylamino, dialkylamino, N-heterocyclyl and substituted N-beterocyclyl.
Diseases and disorders that respond to therapy with compounds of the invention include cancer, hyperplasia, restenosis, cardiac hypertrophy, immune disorders and inflammation; especially cancer, hyperplasia, restenosis, and cardiac hypertrophy; particularly cancer.
In another aspect, the invention relates to compounds useful in inhibiting KSP kinesin.
The compounds have the structures shown above.
In an additional aspect, the present invention provides methods of screening for compounds that will bind to a KSP kinesin, for example compounds that will displace or compete with the binding of the compositions of the invention. The methods comprise combining a labeled compound of the invention, a KSP kinesin, and at least one candidate agent and determining the binding of the candidate bioactive agent to the KSP kinesin.
In a further aspect, the invention provides methods of screening for modulators of
KSP kinesin activity. The methods comprise combining a composition of the invention, a KSP kinesin, and at least one candidate agent and determining the effect of the candidate bioactive agent on the KSP kinesin activity.
Figure 1 depicts a generic synthetic scheme to make compositions of the invention.
Figure 2 depicts a synthetic route for the synthesis of quinazolinone KSP inhibitors.
Figure 3 depicts representative chemical structures of quinazolinone KSP inhibitors.
Figure 4 depicts a synthetic route to substantially pure single enantiomers.
Figure 5 depicts synthetic routes to sulfonamides (5a), carbamates (5b), ureas (5c) and amines (5d).
The present invention is directed to a class of novel compounds, based on a core quinazolinone structure, that are modulators of mitotic kinesins. By inhibiting or modulating mitotic kinesins, but not other kinesins (e.g., transport kinesins), specific inhibition of cellular proliferation is accomplished. Thus, the present invention capitalizes on the finding that perturbation of mitotic kinesin function causes malformation or dysfunction of mitotic spindles, frequently resulting in cell cycle arrest and cell death. The methods of inhibiting a human KSP kinesin comprise contacting an inhibitor of the invention with a KSP kinesin, particularly human KSP Kinesins, including fragments and variants of KSP. The inhibition can be of the ATP ’ hydrolysis activity of the KSP kinesin and/or the mitotic spindle formation activity, such that the mitotic spindles are disrupted. Meiotic spindles may also be disrupted.
An object of the present invention is to develop inhibitors and modulators of mitotic kinesins, in particular KSP, for the treatment of disorders associated with cell proliferation. Traditionally, dramatic improvements in the treatment of cancer, one type of cell proliferative disorder, have been associated with identification of therapeutic agents acting through novel mechanisms. Examples of this include not only the taxane class of agents that appear to act on microtubule formation, but also the camptothecin class of topoisomerase I inhibitors. The compositions and methods described herein can differ in their selectivity and are preferably used to treat diseases of proliferating cells, including, but not limited to cancer, hyperplasias, restenosis, cardiac hypertrophy, immune disorders and inflammation.
Accordingly, the present invention relates to methods employing quinazolinone amides of formula 1a: 0 Re
R Re “NN ]
Re' x
N Ry 0 N hi NR,
Re 1a quinazolinone sulfonamides of formula 1b 0 Re
R Re
BN wl]
Ry" Nn . N Ry
N Re il
Ry 1b and quinazolinone amines of formulae 1c and 1d 0 Re
R Re
Ny
Re
Re! xX
N Ry
N Re vd Nr lc 0 Rs
Ry Re
Ny no]
Re’ "Nn.
ON Re
N Re [
Re 1d wherein:
R, is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, and substituted alkylbeteroaryl;
Ry and Ry’ are independently chosen from hydrogen, alkyl, oxaalkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, and substituted alkylheteroaryl; or Ra and Ry’ taken together form a 3- to 7-membered ring;
= ®
Rj is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, substituted alkylheteroaryl, oxaalkyl, oxaalkylaryl, substituted oxaalkylaryl, oxaalkylheteroaryl, substituted oxaalkylheteroaryl, R1sO- and Ris-NH-;
Ry is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, substituted alkylheteroaryl, and Rys-NH-
Ry is chosen from alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, and substitated alkyiheteroaryl;
Ry is chosen from hydrogen, alkyl, ary], alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, substituted alkytheteroaryl, and R;¢-alkylene-;
Rs, Re, Ry and Ry are independently chosen from hydrogen, alkyl, alkoxy, halogen, fluoroalkyl, nitro, cyano, dialkylamino, alkylsulfonyl, alkyisulfonamido, sulfonamidoalkyl, sulfonamidoaryl, alkylthio, carboxyalkyl, carboxamido,
Rys is chosen from alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, alkylheteroaryl;
Ry is chosen from alkoxy, amino, alkylamino, dialkylamino, N-heterocyclyl and substituted N-heterocyclyl.
All of the compounds falling within the foregoing parent genus and its subgenera are useful as kinesin inhibitors, but not all the compounds are novel. In particular, certain ureas (i.e. compounds in which R; is RisNH) are disclosed in US patent 5,756,502 as agents which modify cholecystokinin action. The specific exceptions in the claims reflect applicants’ intent to avoid claiming subject matter that, while functionally part of the inventive concept, is not patentable to them for reasons having nothing to do with the scope of the invention.
The term "optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where said event or circumstance occurs and instances in which it does not. For example, “optionally substituted alkyl” means either “alkyl” or “substituted alkyl,” as defined below. It will be understood by those skilled in the art with respect to any group containing one or more substituents that such groups are not intended to introduce any substitution or substitution patterns (e.g., substituted alkyl includes optionally substituted cycloalkyl groups, which in tum are defined as including optionally substituted alkyl groups, potentially ad infinitum) that are sterically impractical and/or synthetically non-feasible.
Alkyl is intended to include linear, branched, or cyclic hydrocarbon structures and combinations thereof, Lower alkyl refers to alkyl groups of from 1 to 5 carbon atoms.
Examples of lower alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, s-and t-butyl and the like. Preferred alkyl groups are those of Cz or below. More preferred alkyl groups are those of Cys or below. Cycloalkyl is a subset of alkyl and includes cyclic hydrocarbon groups of from 3 to 13 carbon atoms. Examples of cycloalkyl groups include c-propyl, c-butyl, c-pentyl, norbormyl, adamantyl and the like. In this application, alkyl refers to alkanyl, as well as the unsaturated alkenyl and alkynyl residues; it is intended to include cyclohexylmethyl, vinyl, allyl, isoprenyl and the like. Alkylene refers to the same residues as alkyl, but having two points of attachment. Examples of alkylene include ethylene (-CH2CH;-), ethenyiene (-CHz~CHy-), propylene (-CH;CH,CHy-), dimethyipropylene (-CHzC(CH) 2CHz) and cyclohexyipropylene (-CH;CH;CH(C¢His)-). When an alkyl residue having a specific number of carbons is named, all geometric isomers having that number of carbons are intended to be encompassed; thus, for example, “butyl” is meant to include n-butyl, sec-butyl, isobutyl and t-butyl; “propyl” includes n-propyl and isopropyl (or “i-propyl”.
Alkoxy or alkoxyl refers to groups of from 1 to 8 carbon atoms of a straight, branched, cyclic configuration and combinations thereof attached to the parent structure through an oxygen. Examples include methoxy, ethoxy, propoxy, isopropoxy,
oO 0 cyclopropyloxy, cyclohexyloxy and the like. Lower-alkoxy refers to groups containing one to four carbons.
Acyl refers to groups of from 1 to 8 carbon atoms of a straight, branched, cyclic configuration, saturated, unsaturated and aromatic and combinations thereof, attached to the parent structure through a carbonyl functionality. One or more carbons in the acyl residue may be replaced by nitrogen, oxygen or sulfur as long as the point of attachment to the parent remains at the carbonyl. Examples include acetyl, benzoyl, propionyl, isobutyryl, t-butoxycarbonyl, benzyloxycarbonyl and the like. Lower-acyl refers to groups containing one to four carbons.
Aryl and heteroaryl mean a S- or 6-membered aromatic or heteroaromatic ring containing 0-3 heteroatoms selected from O, N, or S; a bicyclic 9- or 10-membered aromatic or heteroaromatic ring system containing 0-3 heteroatoms selected from O,
N, or S; or a tricyclic 13- or 14-membered aromatic or heteroaromatic ring system containing 0-3 heteroatoms selected from O, N, or S. The aromatic 6- to 14- membered carbocyclic rings include, e.g., benzene, naphthalene, indane, tetralin, and fluorene and the 5- to 10-membered aromatic heterocyclic rings includs, e.g., imidazole, pyridine, indole, thiophene, benzopyranone, thiazole, furan, benzimidazole, quinoline, isoquinoline, quinoxaline, pyrimidine, pyrazine, tetrazole and pyrazole.
Alkylaryl refers to a residue in which an aryl moiety is attached to the parent structure via an alkylene residue. Examples arc benzyl, phenethyl, phenylvinyl, phenylallyl and the like. Oxaalkyl and oxaalkylaryl refer to alkyl and alkylaryl residues in which one or more methylenes have been replaced by oxygen. Examples of oxaalkyl and oxaalkylaryl residues are ethoxyethoxyethyl (3,6-dioxaoctyl), benzyloxymethy! and pheaoxymethyl; in general, glycol ethers, such as polyethyleneglycol, are intended to be encompassed by this group. Alkylheteroaryl refers to a residue in which a heteroaryl moiety is attached to the parent structure via an alkylene residue. Examples
Heterocycle means a cycloalkyl or aryl residue in which one to four of the carbons is replaced by a heteroatom such as oxygen, nitrogen or sulfur. Examples of heterocycles that fall within the scope of the invention include imidazoline,
pyrrolidine, pyrazole, pyrrole, indole, quinoline, isoquinoline, tetrahydroisoquinoline, benzofuran, benzodioxan, benzodioxole (commonly referred to as methylenedioxyphenyl, when occurring as a substituent), tetrazole, morpholine, thiazole, pyridine, pyridazine, pyrimidine, thiophene, furan, oxazole, oxazoline, isoxazole, dioxane, tetrahydrofuran and the like. “N-heterocyclyl” refers to a nitrogen-containing heterocycle as a substituent residue. The term heterocyclyl encompasses heteroaryl, which is a subset of heterocyclyl. Examples of
N-heterocyclyl residues include 4-morpholinyl, 4-thiomorpholinyl, 1-piperidinyl, 1-pyrrolidinyl, 3-thiazolidinyl, piperazinyl and 4-(3,4-dihydrobenzoxazinyl). © 10 Examples of substituted heterocyclyl include 4-methyl-1-piperazinyl and 4-benzyl-1-
Substituted alkyl, aryl and heteroaryl refer to alkyl, aryl or heteroaryl wherein one or more H atoms are replaced with alkyl, halogen, hydroxy, alkoxy, alkylenedioxy (e.g., methrylenedioxy), flucroalkyl, carboxy (-COOH), carboalkoxy (i.., acyloxy -O(O)CR), carboxyalkyl (i.c., esters -C(O)OR), carboxamido, sulfonamidoalkyl, sulfonamidoaryl, aminocarbonyl, benzyloxycarbonylamino (CBZ-amino), cyano, carbonyl, nitro, primary-, secondary- and tertiary-amino (e.g., alkylamino and dialkylamino) and aminoektylene, alkylthio, alkyisulfinyl, alkyisulfonyl, alkylsul fonamido, arylthio, arylsulfinyl, arylsulfonyl, amidino, aryl (e.g., phenyl and benzyl), heteroaryl, heterocyclyl, phenoxy, benzyloxy, or hetercaryloxy. For the purpoees of the present invention, substituted alkyl also includes oxaalkyl residues, i.e. alkyl residues in which one or more carbons has been replaced by oxygen.
Substituted alkylaryl and substituted axsalkylaryl refer to residues where either or both of the alkylene and aryl moieties are substituted. Substituted alkylheteroaryl and substituted oxaalkylheteroaryl residues where either or both of the alkylene and heteroaryl moieties are substituted. It should additionally be noted that certain positions may contain two or evea three substitution groups, R, R’ and R” (e.g., diethylamino and trifluoromethyl).
Halogen refers to fluorine, chlorine, bromine or iodine. Fluorine, chlorine and bromine are prefered. Dihaloaryl, dihaloalkyl, trihaloaryl, etc. refer to aryl and alkyl o 0 substituted with a plurality of halogens, but not necessarily a plurality of the same halogen; thus 4-chloro-3-fluorophemnyl is within the scope of dihaloaryl.
Most of the compounds described herein contain one or more asymmetric centers (€.g. the carbon to which R; and Ry’ are attached) and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as (R)- or (S)-. The present invention is meant to include all such possible isomers, including racemic mixtures, optically pure forms and intermediate mixtures. Optically active (R)- and (S)- isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. When . 10 the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, and unless specified otherwise, it is intended that the compounds include both E and Z geometric isomers. Likewise, all tautomeric forms are also intended to be included.
When desired, the R- and S-isomers may be resolved by methods known to those skilled in the art, for example by formation of diastereoisomeric salts or complexes which may be separated, for example, by crystallisation; via formation of diastersoisomeric derivatives which may be separated, for example, by crystallisation, gas-liquid or liquid chromatography; selective reaction of one enantiomer with an enantiomer-specific reagent, for example enzymatic oxidation or reduction, followed by separation of the modified and unmodified enantiomers; or gas-liquid or liquid . chromatography in a chiral environment, for example on a chiral support, such as silica with a bound chiral ligand or in the presence of a chiral solvent. It will be appreciated that where the desired enantiomer is converted into another chemical entity by one of the separation procedures described above, a further step may be required to liberate the desired enantiomeric form. Alternatively, specific enantiomer may be synthesized by asymmetric synthesis using optically active reagents, substrates, catalysts or solvents, or by converting on enantiomer to the other by asymmetric transformation. An example of a synthesis from optically active starting materials is shown in Figure 4.
In one embodiment, as will be appreciated by those in the art, the two adjacent Ry groups may be fused together to form a ring structure. Again, the fused ring structure may contain heteroatoms and may be substituted with one or more substitution groups "R*. It should additionally be noted that for cycloalkyl (i.e., saturated ring structures), certain positions may contain two substitution groups, R and R'.
Considering formulae 1a, 1b, 1c and 1d, but focusing on 1a, in a preferred embodiment R, is selected from hydrogen, alkyl, aryl, substituted alkyl, substituted aryl, heteroaryl, substituted heteroaryl, alkylaryl and substituted alkylaryl.
In a more preferred embodiment R; is selected from hydrogen, lower alkyl, substituted lower alkyl, benzyl, substituted benzyl, phenyl, naphthyl and substituted phenyl.
Ina most preferred embodiment R, is chosen from hydrogen, ethyl, propyl, methoxyethyl, naphthyl, phenyl, bromophenyl, chlorophenyl, methoxyphenyl, ethoxyphearyl, tolyl, dimethylphenyl, chorofiuorophexyl, methyichlorophenyl, cthryiphenyl, phenethyl, benzyl, chlorobenzyl, methylbenzyl, methoxybenzyl, cyanobenzyl, hydroxybenzyl, tetrahydrofuranyimethyl and (ethoxycarbonyl)ethyl.
Ina preferred embodiment R; is hydrogen, alkyl,cycloalkyl or substituted alkyl. As will be appreciated by those in the art, Formulae 1a, 1b, 1c and 1d possess a ] potentially chiral center at the carbon to which Rj is attached. Thus, the R; position may comprise two substitution groups, Ra and Ra’. The R; and Ry’ groups may be the same or different; if different, the composition is chiral, When the R; and Ry’ are different, preferred embodiments utilize only a single non-hydrogen R;. The invention contemplates the use of pure enantiomers and mixtures of enantiomers, including racemic mixtures, although the use of the substantially optically pure eutomer will generally be preferred, particularly the R enantiomer.
In a more preferred embodiment, R; is chosen from hydrogen, lower alkyl and substituted lower alkyl, and Ra’ is hydrogen. In a most preferred embodiment R; is chosen from hydrogen, methyl, ethyl, propyl (particularly i-propyl), butyl (particularly t-butyl), methylthioethyl, aminobutyl, (CBZ)aminobutyl, cyclohexylmethyl, benzyloxymethyl, methylsulfinrylethyl, methylsulfinylmethyl, hydroxymethyl, benzyl and indolylmethyl. Bspecially preferred is the R enantiomer where R; is i-propyl.
2 ®
In a preferred embodiment Ry; is selected from chosen from alkyl, substituted alkyl, alkylaryl, heteroaryl, aryl, substituted aryl, substituted oxaalkylaryl, -O-R,s and -NH-Rs, and Rys is chosen from alkyl, aryl and substituted aryl.
In a more preferred embodiment, when Ry is not -NHRys, Rj is chosen from Ci-Cy3 alkyl; substituted lower alkyl;ary], including phenyl, biphenyl and naphthyl; substituted aryl, including phenyl substituted with one or more halo, lower alkyl, loweralkoxy, nitro, carboxy, methylenedioxy or trifluoromethyl; benzyl; phenoxymethyl; halophenoxymethyl; phenylvinyl; heteroaryl; heteroaryl substituted with lower alkyl; and benzyloxymethyl. Inamost preferred embodiment, when Ry is not -NHR ys, Rs i8 chosen from ethyl, propyl, chioropropyl, butoxy, heptyl, butyl, octyl, tridecanyl, (ethoxycarboryl)ethyl, dimethylaminoethyl, dimethylaminomethyl, phenyl, naphthyl, halophenyl, methoxyphemyl, carboxyphenyl, ethrylphenyl, tolyl, biphenyl, methylenedioxyphenyl, methylsulfonylphenyl, methoxychlorophenyl, chloronaphthyi, methylhalophenyl, trifluoromethyiphenyl, butylphenyl, pentylphenyl, methyinitrophenyl, phenoxymetiryl, dimethoxyphenyl, phenylvinyl, nitrochlorophenryl, nitropheny, dinitropheayl, bis(triffucromethyl)phenyl, benzyloxymethyl, benzyl, furanyl, ‘benzofuranyl, pyridinyl, indolyl, methylpyridinyl, quinolinyl, picolinyl, pyrazolyl, and imidazolyl.
Ina more preferred embodiment, when Ry is -NHRs, Ris is chosen from lower alkyl; cyclohexyl; phenyl; and phenyl substituted with halo, lower alkyl, loweralkoxy, or lower alkylthio.
In a most preferred embodiment, when Rj is -NHRys, Rys is isopropyl, butyl, cyclohexyl, phenyl, bromophenyl, dichlorophenyl, methoxyphenyl, ethylphenyl, tolyl, trifluoromethylphenyl or methylthiophemyl.
In a preferred embodiment Ry is chosen from alkyl, aryl, alkylaryl, alkylheteroaryl, substituted alkyl, substituted aryl, and -alkylene-R1s, and Rig is chosen from alkoxy, amino, alkylamino, dialkylamino and N-heterocyclyl.
2 5
In a more preferred embodiment, Ry is selected from lower alkyl, substituted lower alkyl, cyclohexyl; phenyl substituted with lrydroxy, lower alkoxy or lower alkyl; benzyl; hetsroaryimethyl; heteroarylethyl; heteroarylpropyl and -alkylene-Rig, wherein Ry is amino, lower alkylamino, di(lower alkyl)amino, lower alkoxy, or N- heterocyclyl.
In a most preferred embodiment, Ry is chosen from methyl, ethyl, propyl, butyl, cyclohexyl, carboxyethyl, carboxymethyl, methoxyethyl, kydroxyethyl, hydroxypropyl, dimethylaminoethyl, dimethylaminopropyl, dicthylaminoethyl, diethylaminopropyl, aminopropyl, methylaminopropyl, 2,2-dimethyl-3- (dimethylamino)propyl, 1-cyclohexyl-4-(diethylamino)butyl, aminoethyl, aminobutyl, aminopentyl, aminohexyl, aminoethoxyethyl, isopropylaminopropyl, diisopropylaminoethyl, 1-methyl-4-(diethylamino)butyl, (t-Boc)aminopropyl, hydraxyphenyl, benzyl, methoxyphenyl, methylmethoxyphenyl, dimethytphenyl, tobyl, ethytphenyl, (oxopyrrolidinyl)propyl, (methoxycarbomy)ethiyl, benzylpiperidinyl, pyridinylethyl, pyridinyimetiryl, morpholinylethyl, morpholinylpropyl, piperidinyl, azetidinylmethyl, azetidimylpropyl, pymrolidinylethyl, pyrrotidinylpropyl, piperidinylmethyl, piperidinylethyl, imidazolylpropyl, imidazolyletryl, (cthrylpyrrolidinylmethyl, (methytpyrrolidinyl)ethyl, (methylpiperidinylpropyl, (methylpiperazinylpropyl, furanytmethyl and indolylethryl
In other preferred embodiments, Rs, Rg, R7 and Ry are chosen from hydrogen, halo . (particularly chloro and fluoro), lower alkyl (particularly methyl), substituted lower alkyl (particularly trifluoromethyl), lower alkoxy (particularly methoxy), and cymo; more preferably from hydrogen and halo. Further preferred for each of the specific substituents: Rg is hydrogen or halo; Ry is hydrogen, methyl or halo; R, is hydrogen, halo, alkyl (particularly methyl), alkoxy (particularly methoxy) or cyano; and Ris hydrogen or halo. Still further preferred are the compounds where only one of Rs, Re,
Ry; and Ry is not hydrogen, especially Rs.
In a particularly preferred subgenus, R; is benzyl or halobenzyl; R; is chosen from ethyl and propyl; Ro’ is hydrogen; Rs (or Ry: or Ry) is substituted phenyl; Ry is — (CHa)nOH where m is two or three, or (CHg)p Ris where p is one to three and Ry; is amino, propylamino or azetidinyl; Rs is hydrogen; Re is hydrogen; Ry is halo; and Ry is hydrogen.
When considering primarily the sulfonamides of formula 1b, R is preferably chosen from hydrogen, lower alkyl, substituted lower alkyl, benzyl, substituted benzyl, phenyl and substituted phenyl; R; is chosen from hydrogen and lower alkyl and R;’ is hydrogen; Rj is chosen from C;-C,3 alkyl; phenyl; naphthyl; phenyl substituted with halo, lower alkyl, lower alkoxy, nitro, methylenedioxy, or trifluoromethyl; biphenylyl and heteroaryl; and Ry is chosen from lower alkyl, cyclohexyl; phenyl substituted with hydroxy, lower alkoxy or lower alkyl; benzyl; heteroarylmethyl; heteroarylethyl; heteroaryipropyl; heteroarylethyl; heteroaryipropyl and -alkylene-Ri¢, wherein Ry is " di(lower alkyl)amino, (lower alkyl)amino, amino, lower alkoxy, or N-beterocyclyl, particularly pyrrolidino, piperidino or imidazolyl.
When considering primarily the sulfonamides of formula 1b, R; is most preferably . chosen from lower alkyl, benzyl, substituted benzyl and substituted phenyl; R; is hydrogen or lower alkyl; Ry’ is hydrogen; R; is chosen from substituted phenyl and naphthyl; Ry is -alkyleno-Rig; Ry is hydrogen, fluoro, methyl or chloro; Rg, Rg and Ry are hydrogen; and Rj is chosen from di(lower alkylamino), (lower alkyl)amino, amino, pyrrolidino, piperidino, imidazolyl and morpholino. :
When considering primarily the amines of formulae 1c and 1d, R; is preferably chosen from hydrogen, lower alkyl, substituted lower alkyl, benzyl, substituted benzyl, phenyl, naphthyl and substituted phenyl; R; is chosen from hydrogen, lower alkyl and substituted lower alkyl and R,’ is hydrogen; Rs is chosen from C,-C); alkyl; : substituted lower alkyl; phenyl; naphthyl; phenyl substituted with halo, lower alkyl, lower alkoxy, nitro, methylenedioxy, or trifluoromethyl; biphenylyl, benzyl and heterocyclyl; and R, is chosen from lower alkyl; cyclohexyl; phenyl substituted with hydroxy, lower alkoxy or lower alkyl; benzyl; substituted benzyl; heterocyclyl; heteroaryimethyl; heteroarylethyl; heteroarylpropyl and -alkylene-R;¢, wherein Ry¢ is di(lower alkyl)amino, (lower alkyl)amino, amino, lower alkoxy, or N-heterocyclyl.
When considering primarily the amines of formulae 1c and 1d, R; is most preferably chosen from lower alkyl, benzyl, substituted benzyl and substituted phenyl; R; is hydrogen or lower alkyl; Ry’ is hydrogen; Ry is chosen from substituted phenyl, heterocyclyl and naphthyl; Ry is chosen from subtituted benzyl, heterocyclyl and . -alkylene-R;; Rs and R; are chosen from hydrogen and halo; Rs and Ry are hydrogen; and R¢ is chosen from di(lower alkylamino), (lower alkyl)amino, amino, pyrrolidinyl, : 5 piperidinyl, imidazolyl and morpholinyl. When R;- is present (as in 1d) it is most preferably chosen from halophenyl, polyhalophenyl, tolyl, dimethytphenyl, methoxyphenyl, dimethoxyphenyl, cyanophenyl, triflucromethylphenyl, trifluoromethoxyphenyl, bis(trifluoromethyl)phenyl, carboxyphenyl, t-butylphenyl, methoxycarbonylphenyl, piperidinyl and naphthyl.
In view of the foregoing, particularly when taken in consideration of the test data presented below, it will be appreciated that preferred for the compounds, pharmaceutical formulations, methods of manufacture and use of the present invention are the following combinations and permutations of substituent groups (sub- grouped, respectively, in increasing order of preference): ‘ 1. Any of formulas la, 1b, lc or 1d (preferably formulae 1a or 1d) where R, is hydrogen, lower alkyl, substituted lower alkyl, alkylaryl or substituted alkylaryl (preferably benzyl or substituted benzyl): : a. Especially where the stereogenic center to which R; and R;’ are attached is of the R configuration, where Ry is hydrogen.
C20 i. Particularly where R; is lower alkyl (preferably ethyl, i-proyl, c-propyl or t-butyl). 1. Most preferably where R; is i-propyl. - b. * Especially those where Ry is substituted alkyl, (preferably a primary-, secondary- or tertiary-smino-substituted lower alkyl). i. Most preferably where Ry is primary-amino lower alkyl. c. Especially those where Rg, Rs, R7 and Rg are chosen from hydrogen, halo, lower alkyl (preferably methyl), substituted lower alkyl, lower alkoxy (preferably methoxy), and cyano. i. Preferably Rs, Re, and Ry are hydrogen. 1. More preferably Ry is halo or cyano, especially fluoro or chloro, and most prefombly chloro.
CB ® d. In the case of formulae 1a and 1d, especially those where R; or R;- is aryl (preferably phenyl), substituted aryl (preferably lower alkyl- or lower alkoxy-substituted phenyl), alkylaryl (preferably benzyl and phenylviny), alkylheteroaryl, oxaalkylaryl (preferably phenoxy lower alkyl), oxaalkylheteroaryl, substituted alkylaryl (preferably substituted benzyl and substituted phenylviny), substituted alkylheteroaryl, substituted oxaalkylaryl (preferably substituted phenoxy lower alkyl), or substituted oxaalkylheteroaryl. i. Most preferably those where R; or Ry- is aryl, substituted aryl, lower alkylaryl or substituted lower alkylaryl. 2. Any of formulae 1a, 1b, 1c or 1d, where the stereogenic center to which R; and
Ry’ are attached is of the R configuration, particularly where Ry: is hydrogen: a. Especially where Ry is lower alkyl (preferably ethyl, i-proyl, c-propyl or t-butyl). i Most preferably where R; is i-propyl. b. Especially where Ry is substituted alkyl (preferably a primary-, secondary- or tertiary-amino-substituted lower alkyl). i. Most preferably where Ry is primary amino-lower alkyl. c. Especially where Rs, Rg, and Ry are hydrogen. i. Most preferably where R; is hydrogen, halo (particularly chloro or fluoro), lower alkyl (particularly methyl), substituted lower alkyl, lower alkoxy (particularly methoxy), or cyano 1. Especialy where Ry is chloro. 3. Any of formulae 1a, 1b, 1c or 1d where Ry is hydrogen, halo (preferably chloro or fluoro), lower alkyl (preferably methyl), substituted lower alkyl, lower alkoxy (preferably methoxy), or cyano. a. Especially those where Ry is halo or cyano. ' b. Especially those where Rs, Re, and Rg are hydrogen. i. Most preferably those where Ry is chloro.
4. Any of formulae 1b or lc, where Ry is substituted alkyl (preferably a primary-, secondary- or tertiary-amino-substituted lower alkyl, especially primary-amino lower alkyl). a. Especially where the stereogenic center to which R; and Ry’ are attached is of the R configuration, particularly where Ry is hydrogen: i Especially where R; is lower alkyl (preferably ethyl, i-proyl, c-propyl or t-butyl). 1. Most preferably where R; is i-propyl. b. Especially where Rs, Re, and Ry are hydrogen. i. Most preferably where R; is hydrogen, halo (particularly chloro or fluoro), lower alkyl (particularly methyl), substituted lower alkyl, : lower alkoxy (particularly methoxy), or cyano 1. Bspecialy where R; is chloro.
Most preferred for the compounds, pharmaceutical formulations, methods of manufacture and use of the present invention is formula 1a incorporating the following combinations and permutations of substituent groups (sub-grouped, respectively, in increasing order of preference): 1. Ry is alkylaryl or substituted alkylaryl (preferably benzyl or substituted benzyl, most preferably benzyl). a. Especially where the stereogenic center to which R; and R;’ are attached is . of the R configuration, where R;’ is hydrogen. i. Particularly those where R; is lower alkyl (preferably ethyl, i-propyl, c-propyl or t-butyl). 1. Most preferably those where R; is i-propyl. b. Especially those where Rj is aryl (preferably phenyl), substituted aryl (preferably lower alkyl-, lower alkoxy- and/or halo-substituted phenyl), alkylaryl (proferably benzyl and pheaylviny), alkylheteroaryl, oxaalkylaryl (preferably phenoxy lower alkyl), oxaalkylheteroaryl, substituted alkylaryl (preferably substituted benzyl and substituted phenylviny), substituted alkylheteroaryl, substituted oxaalkylaryl (preferably substituted phenoxy lower alkyl), or substituted oxaalkylheteroaryl.
i.
Particularly those where Ry is aryl, substituted aryl, lower alkylaryl, substituted lower alkylaryl, oxa(lower)alkylaryl. 1. Most preferably those where R; is methyl- and/or halo-substituted phenyl. c.
Especially those where Ry is substituted alkyl (preferably a primary-, secondary- or tertiary-amino-substituted lower alkyl). i.
Particularly those where Ryis a primary-amino-substituted lower alkyl. 1. Most preferably those where Ry is 3-amino-n-propyl. d.
Especially those where Rs, Rg, Ry and Ry are chosen from hydrogen, halo (preferably chloro and fluoro), lower alkyl (preferably methyl), substituted "lower alkyl, lower alkoxy (preferably methoxy), and cyano. i.
Particularly those where Rs, Rg, R7 and Ry are hydrogen, halo, lower alkyl or cyano. 1. Most preferably those where Rs, Re and Ry are hydrogen. a.
Especially those where Ry is halo or cymno (most preferably chloro). 2. Especially those where Ry is halo or cyano (most preferably chloro). : 2. Where the stercogenic center to which Ro and Ry’ are sttached is of the R configuration (preferably where Ry” is hydrogen). a Especially those where Rj is lower alkyl (preferably ethyl, i-propyl, c-propyl or t-butyl). i.
Most preferably those where R; is i-propyl.
b.
Especially those where R; is aryl (preferably phenyl), substituted aryl (preferably lower alkyl-, lower alkoxy-, and/or halo-substituted phenyl), slkylaryl (preferably benzyl and pheaylviny), alkylheteroaryl, oxaalkylaryl (preferably phenoxy lower alkyl), oxaslkyiheteroaryl, substituted alkylaryl (preferably substituted benzyl and substituted phenylviny), substituted alkytheteroaryl, substituted oxaalkylaryl (preferably substituted phenoxy lower alkyl), or substituted esasliyumroasy
= i.
Particularly those where Rj is aryl, substituted aryl, lower alkylaryl, substituted lower alkylaryl, oxa(lower)alkylaryl. 1. Most preferably those where Rj is methyl- and/or halo-gubstituted phenyl. c.
Especially those where Ry is substituted alkyl (preferably a primary-, secondary- or tertiary-amino-substituted lower alkyl). i.
Particularly those where Ry, is a primary-amino-substituted lower alkyl. 1. Most preferably those where Ry is 3-amino-n-propyl.
d.
Especially those where Rg, Rg, Ry and Rg are chosen from hydrogen, halo (preferably chloro and fluoro), lower alkyl (preferably methyl), substituted lower alkyl, lower alkoxy (preferably methoxy), and cyano.
i.
Particularly those where Rs, Re, R7 and Rg are hydrogen, halo or lower alkyl.
1. Most preferably those where Rs, Rg and Ry are hydrogen.
a.
Especially those where R7 is halo or cyano (most preferably chloro). 2. Especially those where R; is halo or cyano (most preferably chloro). : 3. Ryis aryl (preferably phenyl), substituted aryl (preferably lower alkyl-, lower alkoxy-, and/or halo-substituted phenyl), alkylaryl (preferably benzyl and phenylviny), alkyiheteroaryl, oxaalkylaryl (preferably phenoxy lower alkyl), oxaalkyTheteroaryl, substituted alkylaryl (preferably substituted benzyl and substituted phenylviny), substituted alkylheteroaryl, substituted oxaalkylaryl (preferably substituted phenoxy lower alkyl), or substituted oxaalkylheteroaryl. a.
Especially those where R; is aryl, substituted aryl, lower alkylaryl, substituted lower alkylaryl, oxa(lower)alkylaryl. i.
Most preferably those where R; is methyl- and/or halo-substituted phenyl. : : b.
Especially those where Ry is substituted alkyl (preferably a primary-, secondary- or tertiary-amino-substituted lower alkyl).
= &
i.
Particularly those where Ry is a primary-amino-substituted lower alkyl. 1. Most preferably those where Ry is 3-amino-n-propyl. c.
Especially those where Rs, Rg, Ry and Rg are chosen from hydrogen, halo (preferably chloro and fluoro), lower alkyl (preferably methyl), substituted lower alkyl, lower alkoxy (preferably methoxy), and cyano. i.
Particularly those where Rs, Rg, R7 and Rg are hydrogen, halo, lower alkyl or cyano. 1. Most preferably those where Rs, Rs and Rg are hydrogen. a.
Especially those where Rs is halo or cyano (most preferably chloro). 2. Especially those where R; is halo or cyano (most preferably chloro). 4. Ry is substitated alkyl (preferably a primary-, secondary- or tertiary-amino- substituted lower alkyl). a.
Particularly those where R4 is a primary-smino-substituted lower alkyl. i.
Most preferably those where Ry is 3-amino-n-propyl. b.
Especially those where Rs, Re, R7 and Rg are chosen from hydrogen, halo (preferably chloro and fluoro), lower alkyl (preferably methyl), substituted lower alkyl, lower alkoxy (preferably methoxy), and cyano. i Particularly those where Rs, Rg, R7 and Rg are hydrogen, halo, lower alkyl or cyano. 1. Most preferably those where Rs, Rs and Rg are hydrogen. a.
Especially those where R1 is halo or cyano (most preferably chloro). 2. Especially those where Ry is halo or cyano (most preferably chloro). 5. Rs, Re, Ry and Ry are chosen from hydrogen, halo (preferably chloro and fluoro), lower alkyl (preferably methyl), substituted lower alkyl, lower alkoxy (preferably methoxy), and cyano.
a. Especially those where Rs, Re, R7 and Ry are hydrogen, halo, lower alkyl or : cyano. i. Most preferably those where Rs, Rg and Ry are hydrogen. 1. Especially those where R; is halo or cyano (most preferably chloro). ii. Especially those where Rs is halo or cyano (most preferably chloro).
Especially preferred for the compounds, pharmaceutical formulations, methods of manufacture and use of the present invention is formula 1a where R, is alkylaryl or substituted alkylaryl (particularly benzyl or substituted benzyl), R; is lower alkyl (particularly i-propyl), Ro’ is hydrogen, R is substituted aryl (particularly methyl- and/or halo-substituted phenyl), Ry is substituted alkyl (particularly 3-amino-n-propyl), Rs, Rg and Rg are hydrogen, and Ry is halo or cyano (particularly chloro), where the stereogenic center to which R; and R,’ are attached is of the R configuration.
Synthesis, Testing and U
The compositions of the invention are synthesized as outlined below, utilizing techniques well known in the art. For example, as described in Ager et al,, J. of Mod.
Chem. 20:379-386 (1977), hereby incorporated by reference, quinazolinones can be obtained by acid-catalyzed condensation of N-acylanthranilic acids with aromatic primary amines. Other processes for preparing quinazolinones are described in U.S.
Patent applications 5,783,577, 5,922,866 and 5,187,167, all of which are incorporated by reference. oo
The compositions of the invention may be made as shown in Figures 1,2,4 and 5.
Compounds of formulae 1d are made in analogous fashion to Figure 1, except that the acyl halide in the final step is replaced by an alkyl halide.
Once made, the compositions of the invention find use in a variety of applications. As will be appreciated by those in the art, mitosis may be altered in a variety of ways, that is, one can affect mitosis either by increasing or decreasing the activity of a component in the mitotic pathway. Stated differently, mitosis may be affected (e.g.,
® & disrupted) by disturbing equilibrium, either by inhibiting or activating certain components. Similar approaches may be used to alter meiosis.
In a preferred embodiment, the compositions of the invention are used to modulate mitotic spindle formation, thus causing prolonged cell cycle arrest in mitosis. By "modulate" herein is meant altering mitotic spindle formation, including increasing and decreasing spindle formation. By "mitotic spindle formation" herein is meant organization of microtubules into bipolar structures by mitotic kinesins. By “mitotic spindle dysfunction” herein is meant mitotic arrest and monopolar spindle formation.
The compositions of the invention are useful to bind to and/or modulate the activity of a mitotic kinesin, KSP. In a preferred embodiment, the KSP is human KSP, although
KSP kinesins from other organisms may also be used. In this context, modulate means either increasing or decreasing spindle pole separation, causing malformation, i.e., splaying, of mitotic spindle poles, or ofherwise cansing morphological perturbation of the mitotic spindle. Also included within the definition of KSP for these purposes are variants and/or fragments of KSP. See U.S. Patent Application "Methods of Screening for Modulators of Cell Proliferation and Methods of
Diagnosing Cell Proliferation States”, filed Oct. 27, 1999 (U.S. Serial Number 09/428,156), hereby incorporated by reference in its entirety. In addition, other mitotic kinesins may be used in the present invention. However, the compositions of the invention have been shown to have specificity for KSP.
For assay of activity, generally either KSP or a compound according to the invention is non-diffusably bound to an insoluble support having isolated sample receiving areas (¢.g., & microtiter plate, an array, etc.). The insoluble support may be made of any composition to which the compositions can be bound, is readily separated from soluble material, and is otherwise compatible with the overall method of screening.
The surface of such supports may be solid or porous and of any convenicat shape.
Examples of suitable insoluble supports include microtiter plates, arrays, membranes ’ and beads. These are typically made of glass, plastic (e.g., polystyrene), polysaccharides, nylon or nitrocellulose, Teflon™, etc. Microtiter plates and arrays are especially convenient because a large number of assays can be carried out simultaneously, using small amounts of reagents and samples. The particular manner of binding of the composition is not crucial so long as it is compatible with the reagents and overall methods of the invention, maintains the activity of the composition and is nondiffusable. Preferred methods of binding include the use of . antibodies (which do not sterically block cither the ligand binding site or activation sequence when the protein is bound to the support), direct binding to "sticky" or ionic supports, chemical crosslinking, the synthesis of the protein or agent on the surface, etc. Following binding of the protein or agent, excess unbound material is removed by washing. The sample receiving areas may then be blocked through incubation with bovine serum albumin (BSA), casein or other innocuous protein or other moiety.
The antimitotic agents of the invention may be used on their own to modulate the activity of a mitotic kinesin, particularly KSP. In this embodiment, the mitotic agents of the invention are combined with KSP and the activity of KSP is assayed. Kinesin activity is known in the art and includes one or more kinesin activities. Kinesin activities include the ability to affect ATP hydrolysis; microtubule binding; gliding and polymerization/depolymerization (effects on microtubule dynamics); binding to other proteins of the spindle; binding to proteins involved in cell-cycle control, serving as a substrate to other enzymes; such as kinases or proteases; and specific kinesin cellular activities such as spindle pole separation. ,
Methods of performing motility assays are well known to those of skill in the art. [See e.g., Hall, et al. (1996), Biophys. J., 71: 3467-3476, Tumer etal., 1996, AnaL
Biochem. 242 (1):20-5; Gittes et al., 1996, Biophys. J. 70(I): 418-29; Shirakawa et al., 1995, J. Exp. BioL, 198; 1809-15; Winkelmann et al., 1995, Biophys. J. 68: 2444-53;
Winkelmann et al., 1995, Biophys. J. 68: 72S.]
Methods known in the art for determining ATPase hydrolysis activity also can be used. Preferably, solution based assays are utilized. U.S. application 09/314,464, filed May 18, 1999, hereby incorporated by reference in its entirety, describes such assays. Altematively, conventional methods are used. For example, P; release from kinesin can be quantified. In one preferred embodiment, the ATPase hydrolysis activity assay utilizes 0.3 M PCA (perchloric acid) and malachite green reagent (8.27 mM sodium molybdate II, 0.33 mM malachite green oxalate, and 0.8 mM Triton X-1 00). To perform the assay, 10 pL of reaction is quenched in 90 pL of cold 0.3 M
D o
PCA. Phosphate standards are used so data can be converted to mM inorganic phosphate released. When all reactions and standards have been quenched in PCA, 100 pL of malachite green reagent is added to the relevant wells in e.g., a microtiter plate. The mixture is developed for 10-15 minutes and the plate i8 read at an absorbance of 650 nm. If phosphate standards were used, absorbance readings can be converted to mM P; and plotted over time. Additionally, ATPase assays known in the art include the luciferase assay.
ATPase activity of kinesin motor domains also can be used to monitor the effects of modulating agents. In one embodiment ATPase assays of kinesin are performed in the absence of microtubules. In another embodiment, the ATPase assays are performed in the presence of microtubules. Different types of modulating agents can be detected in the above assays. In a preferred embodiment, the effect of a modulating agent is ) independent of the concentration of microtubules and ATP. In another embodiment, the effect of the agents on kinesin ATPase can be decreased by increasing the concentrations of ATP, microtubules or both. In yet another embodiment, the effect of the modulating agent is increased by increasing concentrations of ATP, microtubules or both.
Agents that modulate the biochemical activity of KSP in vitro may then be screened in vivo. Methods for such agents in vivo include assays of cell cycle distribution, cell viability, or the presence, morphology, activity, distribution, or amount of mitotic spindles. Methods for monitoring cell cycle distribution of a cell population, for example, by flow cytometry, are well known to those skilled in the art, as are methods for determining cell viability. See for example, U.S. Patent Application "Methods of
Screening for Modulators of Cell Proliferation and Methods of Diagnosing Cell
Proliferation States,” filed Oct. 22, 1999, serial number 09/428,156, hereby incorporated by reference in its entirety.
In addition to the assays described above, microscopic methods for monitoring spindle formation and malformation are well known to those of skill in the art (see, e.g.
Whitehead and Rattner (1998), J. Cell Sci. 111:2551-61; Galgio et al, (1996) J. Cell biol, 135:399-414).
The compositions of the invention inhibit the KSP kinesin. One measure of inhibition is ICso, defined as the concentration of the composition at which the activity of KSP is decreased by fifty percent. Preferred compositions have ICs's of less than about 1 mM, with preferred embodiments having ICsq's of less than about 100 uM, with more preferred embodiments having ICsq's of less than about 10 uM, with particularly preferred embodiments having ICso's of less than about 1 uM, and especially preferred embodiments having ICsq's of less than about 100 nM, and with the most preferred embodiments having ICso's of less than about 10 nM. Measurement of ICs is done using an ATPase assay.
Another measure of inhibition is K;. For compounds with ICso's less than 1 uM, the
K; or Kq is defined as the dissociation rate constant for the interaction of the quinazolinone with KSP. Preferred compounds have K's of less than about 100 uM, with preferred embodiments having K{'s of less than about 10 uM, and particulady preferred embodiments having K's of less than about 1 pM and especially preferred embodiments having K's of less than about 100 nM, and with the most preferred embodiments having K's of less than about 10 nM. The K| for a compound is determined from the ICs based on three assumptions, First, only one compound molecule binds to the enzyme and there is no cooperativity. Second, the concentrations of active enzyme and the compound tested are known (i.e., there are no significant amounts of impurities or inactive forms in the preparations). Third, the enzymatic rate of the enzyme-inhibitor complex is zero. The rate (i.e., compound concentration) data are fitted to the equation: . - _— 8 (Bo + Ip + Ka). (Bo +l + RAP-4Koly 28,
Where V is the observed rate, Vig is the rate of the free enzyme, I is the inhibitor concentration, By is the enzyme concentration, and Ky is the dissociation constant of the enzyme-inhibitor complex.
Another measure of inhibition is Glsg, defined as the concentration of the compound that results in a decrease in the rate of cell growth by fifty percent. Preferred compounds have Glso's of less than about 1 mM. The level of preferability of embodiments is a function of their Gls : those having Glso's of less than about 20 uM are more preferred; those having Glsy's of 10 uM more so; those having Glso of less than about 1 pM more 50; those having Glsg's of 100 nM more 80; those having Gls of less than about 10 nM even more so. Measurement of Gls is done using a cell proliferation assay.
The compositions of the invention are used to treat cellular proliferation diseases.
Disease states which can be treated by the methods and compositions provided herein include, but are not limited to, cancer (further discussed below), autoimmune discase, arthritis, graft rejection, inflammatory bowel disease, proliferation induced after medical procedures, including, but not limited to, surgery, angioplasty, and the like. It is appreciated that in some cases the cells may not be in a hyper or hypo proliferation state (abnormal state) and still require treatment. For example, during wound healing, the cells may be proliferating "normally", but proliferation enhancement may be desired. Similarly, as discussed above, in the agriculture arena, cells may be ina normal” state, but proliferation modulation may be desired to enhance a crop by directly enhancing growth of a crop, or by inhibiting the growth of a plant or organism which adversely affects the crop. Thus, in one embodiment, the invention herein includes application to cells or individuals afflicted or impending affliction with any one of these disorders or states.
The compositions and methods provided herein are particularly deemed useful for the treatment of cancer including solid tumors such as skin, breast, brain, cervical carcinomas, testicular carcinomas, etc. More particularly, cancers that may be treated by the compositions and methods of the invention include, but are not limited to:
Cardiac: sarcoma (angiosarcoma, fibrosarcoma, rhabdomyosarcoma, liposarcoma), myxoma, thabdomyoma, fibroma, lipoma and teratoma; Lung: bronchogenic carcinoma (squamous cell, undifferentiated small cell, undifferentiated large cell, adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial adenoma, sarcoma, lymphoma, chondromatous hamartoma, mesothelioma; Gastrointestinal: esophagus
(squamous cell carcinoma, adenocarcinoma, leiomyosarcoma, lymphoma), stomach (carcinoma, lymphoma, leiomyosarcoma), pancreas (ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid tumors, vipoma), small bowel (adenocarcinoma, lymphoma, carcinoid tumors, Karposi's sarcoma, leionryoma, hemangioma, lipoma, neurofibroma, fibroma), large bowel (adenocarcinoma, tubular adenoma, villous adenoma, hamartoma, leiomyoma); Genitourinary tract: kidney - (adenocarcinoma, Wilm's tumor [nephroblastoma}, lymphoma, leukemia), bladder and urethra (squamous cell carcinoma, transitional cell carcinoma, adenocarcinoma), prostate (adenocarcinoma, sarcoma), testis (seminoma, teratoma, embryonal carcinoma, teratocarcinoma, choriocarcinoma, sarcoma, interstitial cell carcinoma, fibroma, fibroadenoma, adenomatoid tumors, lipoma); Liver: hepatoma . (hepatocellular carcinoma), cholangiocarcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, hemangioma; Bone: osteogenic sarcoma (osteosarcoma), malignant lymphoma (reticulum cell sarcoma), multiple myeloma, malignant giant cell tumor chordoma, osteochronfroma (osteocartilaginous exostoses), benign chondroma, chondroblastoma, chondromyxofibroma, osteoid osteoma and giant cell tumors; Nervous system: skull (osteoma, hemangioma, granuloma, xanthoma, osteitis deformans), meninges (meningioma, meningiossrcoma, gliomatosis), brain (astrocytoma, medulloblastoma, glioma, ependymoma, germinoma [pinealoma), glioblastoma multiform, oligodendroglioma, schwannoma, retinoblastoma, congenital tumors), spinal cord neurofibroma, meningioma, glioma, sarcoma); Gynecological: uterus (endometrial carcinoma), cervix (cervical carcinoma, pre-tumor cervical dysplasia), ovaries (ovarian carcinoma [serous cystadenocarcinoma, mucinous cystadenocarcinoma, unclassified carcinoma], grannlosa-thecal cell tumors, Sertoli-
Leydig cell tumors, dysgerminoma, malignant teratoma), vulva (squamous cell carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, melanoma), vagina (clear cell carcinoma, squamous cell carcinoma, botryoid sarcoma (embryonal rhabdomyosarcoma], fallopian tubes (carcinoma); Hematologic: blood (myeloid leukemia [acute and chronic), acute lymphoblastic leukemia, chronic lymphocytic leukemia, myeloproliferative diseases, multiple myeloma, myelodysplastic syndrome),
Hodgkin's disease, non-Hodgkin's lymphoma [malignant lymphoma}; Skin: malignant melanoma, basal cell carcinoma, squamous cell carcinoma, Karposi's sarcoma, moles dysplastic nevi, lipoma, angioma, dermatofibroma, keloids, psoriasis; and Adrenal glands: neuroblastoma. Thus, the term “cancerous cell” as provided herein, includes a cell afflicted by any one of the sbove-identified conditions.
Accordingly, the compositions of the invention are administered to cells. By "administered" herein is meant administration of a therapeutically effective dose of the mitotic agents of the invention to a cell either in cell culture or in a patient. By “therapeutically effective dose" herein is meant a dose that produces the effects for which it is administered. The exact dose will depend on the purpose of the treatment, ) 10 and will be ascertainable by one skilled in the art using known techniques. As is known in the art, adjustments for systemic versus localized delivery, age, body weight, general health, sex, diet, time of administration, drug interaction and the severity of the condition may be necessary, and will be ascertainable with routine experimentation by those skilled in the art. By "cells" herein is meant almost any cell in which mitosis or meiosis can be altered.
A "patient" for the purposes of the present invention includes both humans and other animals, particularly mammals, and other organisms. Thus the methods are applicable to both human therapy and veterinary applications. In the preferred embodiment the patient is 8 mammal, and in the most preferred embodiment the patient is human.
Mitotic agents having the desired pharmacological activity may be administered in a physiologically acceptable carrier to a patient, as described herein. Depending upon the manner of introduction, the compounds may be formulated in a variety of ways as . discussed below. The concentration of therapeutically active compound in the formulation may vary from about 0.1-100 wt.%. The agents may be administered . 25 alone or in combination with other treatments, i.e., radiation, or other chemotherapeutic agents.
In a preferred embodiment, the pharmaceutical compositions ae in a water soluble form, such as pharmaceutically acceptable salts, which is meant to include both acid : and base addition salts. "Pharmaceutically acceptable acid addition salt" refers to those salts that retain the biological effectiveness of the free bases and that are not biologically or otherwise undesirable, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid and the like. "Pharmaceutically acceptable base addition salts" include those derived from inorganic bases such as sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like. Particularly preferred are the ammonium, potassium, sodium, calcium, and magnesium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, dicthylamine, triethylamine, tripropylamine, and ethanolamine.
The pharmaceutical compositions can be prepared in various forms, such as granules, tablets, pills, suppositories, capsules, suspensions, salves, lotions and the like.
Pharmaceutical grade organic or inorganic carriers and/or diluents suitable for oral and topical use can be used to make up compositions containing the therapeutically- active compounds. Diluents known to the art include aqueous media, vegetable and animal oils and fats. Stabilizing agents, wetting and emulsifying agents, salts for varying the osmotic pressure or buffers for securing an adequate pH value, and skin penetration enhancers can be used as auxiliary agents. The pharmaceutical compositions may also include one or more of the following: carrier proteins such as serum albumin; buffers; fillers such as microcrystalline cellulose, lactose, corn and other starches; binding agents; sweeteners and other flavoring agents; coloring agents; and polyethylene glycol. Additives are well known in the art, and arc used in a variety of formulations.
The administration of the mitotic agents of the present invention can be done ina variety of ways as discussed above, including, but not limited to, orally, subcutaneously, intravenously, intranasally, transdermally, intraperitoneally,
intramuscularly, intrapulmonary, vaginally, rectally, or intraocularly. In some instances, for example, in the treatment of wounds and inflammation, the anti-mitotic agents may be directly applied as a solution or spray.
To employ the compounds of the invention in a method of screening for compounds that bind to KSP kinesin, the KSP is bound to a support, and a compound of the invention (which is a mitotic agent) is added to the assay. Alternatively, the compound of the invention is bound to the support and KSP is added. Classes of compounds among which novel binding agents may be sought include specific antibodies, non-natural binding agents identified in screens of chemical libraries, : peptide analogs, etc. Of particular interest are screening assays for candidate agents that have a low toxicity for human cells. A wide variety of assays may be used for this purpose, including labeled in vitro protein-protein binding assays, electrophoretic mobility shift assays, immunoassays for protein binding, functional assays (phosphorylation assays, etc.) and the like.
The determination of the binding of the mitotic agent to KSP may be dono in a number of ways. In a preferred embodiment, the mitotic agent (the compound of the invention) is labeled, for example, with a fluorescent or radioactive moiety and binding determined directly. For example, this may be done by attaching all or a portion of KSP to a solid support, adding a labeled mitotic agent (for example a compound of the invention in which at least one atom has been replaced by a detectable isotope), washing off excess reagent, and determining whether the amount of the label is that present on the solid support. Various blocking and washing steps may be utilized as is known in the art.
By "labeled" herein is meant that the compound is either directly or indirectly labeled with a label which provides a detectable signal, .g., radioisotope, fluorescent tag, enzyme, antibodies, particles such as magnetic particles, chemiluminescent tag, or specific binding molecules, etc. Specific binding molecules include pairs, such as biotin and streptavidin, digoxin and antidigoxin etc. For the specific binding members, the complementary member would normally be labeled with a molecule which provides for detection, in accordance with known procedures, as outlined above, The label can directly or indirectly provide a detectable signal.
o &
In some embodiments, only one of the components is labeled. For example, the kinesin proteins may be labeled at tyrosine positions using '°I, or with fluorophores.
Alternatively, more than one component may be labeled with different labels; using 13%] for the proteins, for example, and a fluorophor for the mitotic agents.
The compounds of the invention may also be used as competitors to screen for additional drug candidates. "Candidate bioactive agent" or "drug candidate" or grammatical equivalents as used herein describe any molecule, e.g., protein, oligopeptide, small organic molecule, polysaccharide, polynucleotide, etc., to be tested for bioactivity. They may be capable of directly or indirectly altering the cellular proliferation phenotype or the expression of a cellular proliferation sequence, including both nucleic acid sequences and protein sequences. In other cases, alteration of cellular proliferation protein binding and/or activity is screened. Screens of this sort may be performed either in the presence or absence of microtubules. In the case where protein binding or activity is screened, preferred embodiments exclude molecules already known to bind to that particular protein, for example, polymer structures such as microtubules, and energy sources such as ATP. Preferred embodiments of assays hezein include candidate agents which do not bind the cellular proliferation protein in its endogenous native state termed herein as "exogenous" agents. In another preferred embodiment, exogenous agents further exclude antibodies to KSP.
Candidate agents can encompass numerous chemical classes, though typically they are organic molecules, preferably small organic compounds having a molecular weight of more than 100 and less than about 2,500 daltons. Candidate agents comprise functional groups necessary for structural interaction with proteins, particularly hydrogen bonding and lipophilic binding, and typically include at least an amine, carbonyl, hydroxyl, ether, or carboxyl group, preferably at least two of the finctional chemical groups. The candidate agents often comprise cyclical carbon or heterocyclic structures and/or aromatic or polyaromatic structures substituted with one or more of the above functional groups. Candidate agents are also found among biomolecules including peptides, saccharides, fatty acids, steroids, purines, pyrimidines, derivatives, structural analogs or combinations thereof. Particularly preferred are peptides.
Candidate agents are obtained from a wide variety of sources including libraries of synthetic or natural compounds. For example, numerous means are available for random and directed synthesis of a wide variety of organic compounds and biomolecules, including expression of randomized oligonucleotides. Alternatively, libraries of natural compounds in the form of bacterial, fungal, plant and animal extracts are available or readily produced. Additionally, natural or synthetically produced libraries and compounds are readily modified through conventional chemical, physical and biochemical means. Known pharmacological agents may be subjected to directed or random chemical modifications, such as acylation, alkylation, esterification, amidification to produce structural analogs.
Competitive screening assays may be done by combining KSP and a drug candidate in a first sample. A second sample comprises a mitotic agent, KSP and a drug candidate.
This may be performed in either the presence or absence of microtubules. The binding of the drug candidate is determined for both samples, and a change, or difference in binding between the two samples indicates the presence of an agent capable of binding to KSP and potentially modulating its activity. That is, if the binding of the drug candidate is different in the second sample relative to the first sample, the drug candidate is capable of binding to KSP.
In a preferred embodiment, the binding of the candidate agent is determined through the use of competitive binding assays. In this embodiment, the competitor is a binding moiety known to bind to KSP, such as an antibody, peptide, binding partner, ligand, etc. Under certain circumstances, there may be competitive binding as between the candidate agent and the binding moiety, with the binding moiety displacing the candidate agent.
In one embodiment, the candidate agent is labeled. Either the candidate agent, or the competitor, or both, is added first to KSP for a time sufficient to allow binding, if present. Incubations may be performed at any temperature which facilitates optimal activity, typically between 4 and 40°C.
Incubation periods are selected for optimum activity, but may also be optimized to facilitate rapid high throughput screening. Typically between 0.1 and 1 hour will be sufficient. Excess reagent is generally removed or washed away. The second component is then added, and the presence or absence of the labeled component is followed, to indicate binding.
In a preferred embodiment, the competitor is added first, followed by the candidate agent. Displacement of the competitor is an indication the candidate agent is binding to KSP and thus is capable of binding to, and potentially modulating, the activity of
KSP. In this embodiment, either component can be labeled. Thus, for example, if the competitor is labeled, the presence of label in the wash solution indicates displacement by the agent. Alternatively, if the candidate agent is labeled, the presence of the label on the support indicates displacement.
In an alternative embodiment, the candidate agent is added first, with incubation and washing, followed by the competitor. The absence of binding by the competitor may indicate the candidate agent is bound to KSP with a higher affinity. Thus, if the . candidate agent is labeled, the presence of the label on the support, coupled witha lack of competitor binding, may indicate the candidate agent is capable of binding to
KSP.
It may be of value to identify the binding site of KSP. This can be done in a variety of ways. In one embodiment, once KSP has been identified as binding to the mitotic agent, KSP is fragmented or modified and the assays repeated to identify the necessary components for binding. -
Modulation is tested by screening for candidate agents capable of modulating the activity of KSP comprising the steps of combining a candidate agent with KSP, as above, and determining an alteration in the biological activity of KSP. Thus, in this embodiment, the candidate agent should both bind to KSP (although this may not be necessary), and alter its biological or biochemical activity as defined herein. The methods include both in vitro screening methods and in vivo screening of cells for alterations in cell cycle distribution, cell viability, or for the presence, morpohology, activity, distribution, or amount of mitotic spindles, as are generally outlined above.
Alternatively, differential screening may be used to identify drug candidates that bind to the native KSP, but cannot bind to modified KSP.
ES 50%
Positive controls and negative controls may be used in the assays. Preferably all control and test samples are performed in at least triplicate to obtain statistically significant results. Incubation of all samples is for a time sufficient for the binding of the agent to the protein. Following incubation, all samples are washed free of non- specifically bound material and the amount of bound, generally labeled agent determined. For example, where a radiolabel is employed, the samples may be : counted in a scintillation counter to determine the amount of bound compound.
A variety of other reagents may be included in the screening assays. These include } reagents like salts, neutral proteins, e.g., albumin, detergents, etc which may be used to facilitate optimal protein-protein binding and/or reduce non-specific or background interactions. Also reagents that otherwise improve the efficiency of the assay, such as protease inhibitors, nuclease inhibitors, anti-microbial agents, etc., may be used. The mixture of components may be added in any order that provides for the requisite binding.
The following examples serve to more fully describe the marmer of using the above- described invention, as well as to set forth the best modes contemplated for carrying out various aspects of the invention. It is understood that these examples in no way serve to limit the true scope of this invention, but rather are presented for illustrative purposes. All references cited herein are incorporated by reference in their entirety.
Abbreviations and Definitions
The following abbreviations and terms have the indicated meanings throughout:
Ac = acetyl ’ "25 BNB = 4-bromomethyl-3-nitrobenzoic acid
Boc = t-butyloxy carbonyl
Bu = butyl c- = cyclo .
CBZ = carbobenzoxy = benzyloxycarbonyl
DBU = diazabicyclo[5.4.0Jundec-7-ene
DCM = dichloromethane = methylene chloride = CHCl,
DCE = dichloroethylene
DEAD = diethyl azodicarboxylate
DIC = diisopropylcarbodiimide . Co .37-
DIEA = N,N-diisopropylethyl amine
DMAP = 4NN-dimethylaminopyridine
DMF = N)N-dimethylformamide
DMSO = dimethyl sulfoxide
DVB = ],4-divinylbenzene
EEDQ = 2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline
Et = ethyl
Fmoc = 9-flyorenylmethoxycarbonyl
GC = gag chromatography
HATU = O-(7-Azabenzotriazol-1-y)-1,1,3,3-tetramethyluronium hexaftuorophosphate
HMDS = hexamethyldisilazane
HOAc = acetic acid
HOBt = hydroxybenzotriazole
Me = methyl mesyl = methanesulfonyl
MTBE = methyl t-butyl ether
NMO = N-methylmorpholine oxide
PEG = polyethylene glycol
Ph = phenyl
PhOH = phenol
BPfP = pentafluorophenol
PPTS = pyridinium p-toluenesulfonate
Py = pyridine
PyBroP = bromo-tris-pyrrolidino-phosphonium hexafluorophosphate t = room temperature sat=d = saturated s = socondary t- = tottiary
TBDMS = t-butyldimethylsilyl
TES = ftriethylsilane
TFA = trifluoroacetic acid
THF = tetrahydrofuran
TMOF = trimethyl cxthoformate
TMS = trimethylsilyl tosyl = p-toluenesulfonyl
Tt = triphenylmethyl
Example 40 Synthesis of Compounds
The general synthesis is shown in Figures 1 and 2.
To a three-necked, 500 mL round-bottom flask equipped with a thermometer,
BD M dropping fume, and an efficient magnetic stir bar, was added anthranilic acid (1) (0.5 mole, 68.5 g) and dimethyl formamide (250 mL). To this solution was added butyryl chloride (0.55 mole, 57.1 mL) dropwise at such a rate that the temperature of the mixture did not rise above 40°C. The suspension was stirred vigorously at room temperature for at least an additional 3 h. The mixture was poured into water (2000 mL) and stirred for another 1 h. The precipitated product was collected by filtration, washed with cold water, and dried under reduced pressure over P20, yielding compound 2 (67.3 g, 65%).
Step 2; 2-Propyi-3,1-[4H]benzoxazin-4-one,
Compound 2 (51.8 g, 0.25 mole) was dissolved in acetic anhydride (180 mL) in a 500 mL round-bottom flask equipped with a magnetic stir bar, a Claisen-distillation bead (with vacuum inlet) and a thermometer. The flask was placed in an oil bath and slowly heated to 170-180°C with vigorous stirring. The acetic acid produced was slowly distilled off under atmospheric pressure. Monitoring the head temperature of the distillation ynit was used to follow the progress of the transformation. The reaction mixture was then cooled to 60 °C and the excess of acetic anhydride removed by distillation under reduced pressure (ca. 20 mm Hg). The residue was afterward cooled and the product crystallized. The product was triturated with n-hexane (75 mL) and isolated by filtration to yield 2-propyl-3,1-{4H]benzoxazin-4-one (3) (29.3 g, 62%). The above procedure gave compound 3 sufficiently pure to use directly in the next step.
Compound 3 (28.4 g, 0.15 mole) and benzylamine (17.5 mL, 0.16 mole) were refluxed in chloroform (50 ml) in a one-neck 250 mL round-bottom flask for 6 h.
After complete consumption of compound 3, the chloroform was evaporated under reduced pressure. Ethylene glycol (100 mL) and NaOH pellets (0.60 g) were added to the residue and the flask equipped with a Claisen-distillation head and a magnetic stir bar. The flask was immersed in an oil bath and reheated to 130-140 °C bath temperature with vigorous stirring and maintained there for 5 h while the water produced was removed by distillation. After completion of the reaction, the clear solution was allowed to cool to room temperature and kept overnight to precipitate the product. The pH of the suspension was adjusted to 7-8 by adding 3% aq. HCI, the crystals were filtered off and washed with cold water, and then recrystallized from isopropanol (or alternatively from acetone) to provide the compound, 2-propyl-3- benzylquinazolin-4-one (compound 4) (28.0 g, 67%).
Step 4: 2-(I'bromopropyl)-3-benzylquinazolin-4-one.
To a three-neck 250 mL round-bottom flask equipped with a thermometer, dropping funnel, and efficient magnetic stir bar was added compound 4 (27.8 g, 0. 10 mole), anhydrous sodium acetate (10.0 g) and glacial acetic acid (130 mL). Bromine (16.0 g, 0.10 mole) dissolved in acetic acid (10 mL) was added dropwise to the above solution at40 °C for 1-2 h. After addition was complete, the mixture was poured into water (1500 mL) and stirred for 1-2 h at room temperature. The precipitated product, 241- bromopropyl)-3-benzylquinazolin-4-one (5) was isolated by filtration, washed with warm water fo remove traces of acetic acid, and rinsed with a small amount of isopropanol. Drying yielded compound 5 (33.0 g, 92%). :
Compound 5 (10.7 g, 0.03 mole) and N)N-dimethylethylenediamine (6.6 mL, 0.06 mole) were dissolved in abs. ethanol (60 mL) and heated at reflux for 6 h. After completion of the reaction, the solvent was evaporated under reduced pressure. The residue was dissolved in dichloromethane (150 mL) and washed with 3% aq. NaOH solution (ca. 10-20 mL). The organic layer was dried over MgSO, and evaporated to dryness under reduced pressure. The remaining oily product was purified by flash chromatography on a short silica gel pad using an eluent of CHC1;-MeOH-aq.NH;, 90:10:0.1, to give the desired compound (5), 2{I'-(N,N- dimethylethylenediamino)propyi}-3-benzylquinazolin-4-one (6) (6.0 g, 55%). benzylquinazo ]lin-4-one o
A stock solution of compound 5 (1.822 g, 5.0 mmol) was prepared in HPLC grade
CHCl; (0.5 mL). A stock solution of p-flurobenzoyl chloride (160.2 mg, 1 mmol) in
HPLC grade 1,2-dichloroethane (2.0 mL) was prepared in a 2.0 mL volumetric flask.
A third solution of triethylamine (2.0 mL of 0.5 M) was prepared in HPLC grade 1,2- dichlorethane. A 100 uL aliquot of each solution was pipetted into a glass reaction vessel using a Beckman Biomet 2000 automated liquid dispenser. The reaction mixture was shaken using a mechanical shaker, sonicated in an ultrasonic water bath, and then incubated overnight at room temperature. The mixture was diluted in CHCl, (300 pL) and washed with 5% aqueous NaHCOs and water. The solvent was removed in vacuo to provide compound 6 (65%). The purity of the compound was analyzed by
TLC eluted with CH;Cl-ethanol-concentrated aqueous NH;, 100:10:1. . Examples 2 aud 3
Synthesis of compounds of General Formula 1d oo i
NH -Ry
N oS OO pe Br Ry N ?
DIEA, DMF, CHCl HN
NH~~Reosin
I)R3"Br
DIEA, DCM 0 2)5:590 oor TFA:TBS:DCM
Ry a
Ny r
NH,
All anhydrous solvents were purchased from Aldrich chemical company in SureSeal®
Abbreviations: DCM, dichloromethane; DIEA, N,N-diisopropylethylamine; DMF,
N,N-dimethylformamide; TES, triethylsilane; TFA, trifluoroacetic acid. Array synthesis was conducted in 15 x 75 mm glass round bottom scrow-cap vials contained ina 4 x 6 array aluminum synthesis block, sealed with a Teflon-lined rubber membrane. Reagents were added and aqueous extractions performed with single or multichannel pipettors. Filtrations were performed using Whatman/Polyfiltronics 24 well, 10 mL filtration blocks. Evaporation of volatile materials from the array was performed with a Labconco Vortex-Evaporator or by sweeping with 8 4 x 6 nitrogen manifold
Example 2 (solid phase synthesis of a single compound)
STEP 1: 1,3-Diaminopropane trityl resin (Novabiochem, 1.2 mmol/g) (020g, 024 mmol) was weighed into a screw-cap vial and 3 mL of a 1:1 mixture of DMF and chloroform was added. DIEA (0.130 mL, 0.72 mmol) and 2-(1’-bromopropyl)-3- benzylquinazolin-4-one (from Example 1) (0.188 g, 0.48 mmol) were added. The vial was sealed, heated to 70 °C and shaken overnight. The resin was filtered and washed (3 x DCM, 2 x MeOH, 1 x DCM, 2 x ether) and dried under vacuum. A 27 mg aliquot of resin was treated with 5:5:90 TFA: TES: DCM for 15 min and the mixture was filtered and evaporated, resulting in 8 mg (64% yield) of the quinazolinone- diamine intermediate. LCMS analysis showed >80 % purity.
STEP 2: The resin from Step 1 was swelled in 3 mL of DCM. DIEA (0.130 mL, 0.72 mmol) and 4-bromobenzyl bromide (0.12 g, 0.48 mmol) were added. The vial was scaled and shaken ovemnight. LCMS analysis of a cleaved aliquot revealed an ) approximate 1:1 mixture of starting material and product. Another 0.130 mL of DIEA and 0.12 g of 4-bromobenzyl bromide were added and the mixture was shaken at 70 oC for 8 h. The resin was filtered, washed (as above), and dried under vacuum.
STEP 3: The rosin from Step 2 was twice shaken for 30 min with 5:5:90
TRA:TES:DCM and filtered. The filtrates were combined and evaporated, yielding 140 mg of an orange oil. This material was purified by reverse phase preperative
HPLC (acetonitrile-water gradient) to provide 27 mg (17% for 3 steps) of the mono-
TFA salt.
STEP 1: 1,2-Diaminoethane trityl resin (Novabiochem, 0.95 mmol/g) (200 g, 1.9 mmol) and 1,3-Diaminopropans trityl resin (Novabiochem, 1.14 mmol/g) (2.0 g, 2.28 mmol) were each placed in different 10 mL polypropylene fritted tubes (Bio-Rad). To cach were added 4 mL of DMF, 4 mL of chloroform, 3 eq. of DIEA (1.0 mL and 1.2 mL, respectively) and 2 eq. of 2-(1’-bromopropyi)-3-benzylquinazolin-4-one (from
Example 1) (1.5 g and 1.8 g, respectively). The mixtures were shaken at 70 °C overnight. Each mixture was washed (3 x DCM, 2 x MeOH, 1 x DCM, 2 x ether) and dried under vacuum. Analysis of a cleaved aliquot revealed the presence of the appropriate quinazolinone-diamine for each in >90 % purity.
STEP 2: The quinazolinone cthyl-diamine resin (105 mg, 0.10 mmol) was placed into each of the vials in the first 2 rows of the array, and the quinazolinone propyl-diamine resin (88 mg, 0.10 mmol) was placed into each vial of the last 2 rows of the array. To cach vial was added DIEA (0.131 mL, 0.75 mmol). Into each vial of the first 2 rows of the array was added a different amine, and the additions were repeated for the last two rows of the array. The reaction block was shaken at 70 *C overnight. Liquid was removed from each vial by multichannel pipette using fine-pointed gel-well tips, and the resins were washed (2 x DCM, 1 x MeOH, 1 x DCM) and dried under vacuum.
STEP 3: To each vial of the array was added 2 mL of a 10:5:85 TFA:TES:DCM solution. The reaction block was shaken for 45 min and the mixtures were transferred to a filter block, filtered, and washed twice with 0.75 mL DCM. The solutions were evaporated to yield yellow-to-red oils. These thick oils were triturated twice with ether, dissolved in DCM and treated with 4 M HCI in dioxane to provide the HCI salts (unknown number of salts per compound) as tan-to-white powdery or amarphous solids. Analysis by LCMS showed all to be >75 % pure.
Examples 4-6 :
Six racemic quinazolinones were separated into their enantiomers by chiral chromatography. The chiral chromatography of three of these compounds is described below:
Example 4 5
Bee cl PN 5
Column - Chiralpak AD, 250 x 4.6 mm (Diacel Inc.). Sample —0.5 mg/mL in EtOH.
Conditions — 15 min at 60% EtOH in Hexane, enantiomer 1 elutes at 4.5 min, enantiomer 2 elutes at 4.9 min.
Example § foe. r
POON
NH;
Column - Chiraleel OJ, 250 x 4.6 mm (Diacel Inc.). Sample ~ 0.5 mg/mL in EtOH.
Conditions - 15 min at 10% EtOH in Hexane, (R)-cnantiomer elutes at 8.4 min, (S)- / enantiomer elutes at 9.6 min.
Example 6 oh p
NH,
Column - Chiralpak AD, 250 x 4.6 mm (Diacel Inc.). Sample 0.5 mg/mL in EtOH.
Conditions - 15 min at 70% EtOH in Hexane, enantiomer 1 elutes at 6.5 min, enantiomer 2 elutes at 8.8 min.
The table below depicts the ICs activity of the racemate and the enantiomers of three other compounds separated as above. In all three cases, one enantiomer was significantly more potent than the other. By independent chiral synthesis, it appears that the more active enantiomer is the R enantiomer.
ICso (uM) ICs (0M) ICs (0M)
Racemate | Enantiomer 1 | Enantiomer2
Bee
N
© 12.7 >>40
Ree
SF
© 2.6 >>40 13 u }
Seo ~~
L,
= 5
Examples 7 and 8
The following two compounds were synthesized as single enantiomers by the route shown in Figure 4. The data indicate that the more active enantiomer is the R enantiomer.
I YTV I TT somone mone . oY <0.1 ] 3 h 3 p
Example 9
Chiral Resolution by Recrystallization with Tartaric Acid ’
Intermediate A, prepared in Example 1, can be converted to an intermediate B, which, upon resolution, provides an alternative to the first five steps shown in Figure 4. The process is shown in the scheme below:
E ® oO > 1. NaN,, DMF 0 > joe Ro Ter joe R
X NS X NS
Br NH,
A B
The R enantiomer of B can be crystallized selectively by heating a mixture of B with 1.1 equivalents of D-tartaric acid in a mixture of isopropanol and methanol and then letting the mixture return to room temperature.
Example 9: X=CL, R=H
Racemic intermediate B (1.5 g), dissolved in 100 mL of boiling isopropanol, was mixed with 0.8 g of D-tartaric acid in 100 mL of boiling methanol. The mixture was allowed to slowly reach room temperature. After standing overnight, the solid was removed by filtration and rinsed with ethyl acetate and hexanes, and allowed to air dry. The dried solid (0.8 g) was then dissolved in a boiling mixture of 50 mL of isopropanol and 50 mL of methanol and allowed to slowly cool to room temperature.
After standing overnight, the resulting solid was removed by filtration and rinsed with ethyl acetate and hexanes, and allowed to air dry. The dried solid was then stirred with saturated sodium bicarbonate for 30 min and extracted with ethyl acetate. The organics were dried (MgSO), filtered and evaporated to dryness. The resulting clear oil weighed 345 mg. Chiral purity of >95% was determined by conversion of a portion to the S-Mosher amide and examination of the product by "HNMR.
The enantiomerically pure compounds below were prepared, according to the remaining steps in Figure 4, from material resulting from the procedure described above using both D- and L-tartaric acid.
I = rr rR mw (UM ICgp (UM Cp (UM 2 <0.056 oF
CHy
Example 10
Induction of Mitotic Arrest in Cell Populations Treated with a Quinazolinone KSP 5 Inhibitor
FACS analysis to determine cell cycle stage by measuring DNA content was performed as follows. Skov-3 cells (human ovarian cancer) were split 1:10 for plating in 10cm dishes and grown to subconfinence with RPMI 1640 medium containing 5% fetal bovine serum (FBS). The cells were then treated with either 10nM paclitaxel, 400nM quinazolinone 1, 200nM quinazolinone2, or 025% DMSO (vehicle for compounds) for 24 hours. Cells were then rinsed off the plates with PBS containing
SmM EDTA, pelleted, washed once in PBS containing 1% FCS, and then fixed overnight in 85% ethanol at 4°C. Before analysis, the cells were polleted, washed once, and stained in a solution of 10pg propidium iodide and 250g of ribonuclease (RNAse) A per milliliter at 37°C for half an hour. Flow cytometry analysis was performed on a Becton-Dickinson FACScan, and data from 10,000 cells per sample was analyzed with Modfit software.
The quinazolinone compounds, as well as the known anti-mitotic agent paclitaxel, caused a shift in the population of cells from a GO/G1 cell cycle stage (2n DNA content) to a G2/M cell cycle stage (4n DNA content). Other compounds of this class were found to have similar effects.
Monopolar Spindle Formation following Application of a Quinazolinone KSP . Inhibitor
To determine the nature of the G2/M accumulation, human tumor cell lines Skov-3 (ovarian), HeLa (cervical), and A549 (lung) were plated in 96-well plates at densities . of 4,000 cells per well (SKOV-3 & HeLa) or 8,000 cells per well (A549), allowed to adhere for 24 hours, and treated with various concentrations of the quinazolinone compounds for 24 hours. Cells were fixed in 4% formaldehyde and stained with anti- tubulin antibodies (subsequently recognized using fluorescently-labeled secondary antibody) and Hoechst dye (which stains DNA).
Visual inspection revealed that the quinazolinone compounds caused cell cycle arrest in the prometaphase stage of mitosis. DNA was condensed and spindle formation had initiated, but arrested cells uniformly displayed monopolar spindles, indicating that there was an inhibition of spindle pole body separation. Microinjection of anti-KSP antibodies also canses mitotic arrest with arrested cells displaying monopolar spindles.
Inhibition of Cellular Proliferation in Tumor Cell Lines Treated with Quinazolinone
KSP Inhibitors. : Cells were plated in 96-well plates at densities from 1000-2500 cells/well of a 96-well plate (depending on the cell line) and allowed to adhere/grow for 24 hours. They were then treated with various concentrations of drug for 48 hours. The time at which compounds are added is considered Ty. A tetrazolium-based assay using the reagent 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H- tetrazolium (MTS) (LS> Patent No. 5,185,450) (see Promega product catalog #G3580,
CelITiter 96® AQueos One Solution Cell Proliferation Assay) was used to determine the number of viable cells at To and the number of cells remaining after 48 hours compound exposure. The number of cells remaining after 48 hours was compared to the number of viable cells at the time of drug addition, allowing for calculation of
The growth over 48 hours of cells in control wells that had been treated with vehicle only (0.25% DMSO) is considered 100% growth and the growth of cells in wells with compounds is compared to this. Quinazolinone KSP inhibitors inhibited cell proliferation in human tumor cell lines of the following tumor types: lung (NCI-H460,
A549), breast (MDA-MB-231, MCF-7, MCF-7/ADR-RES), colon (HT29,
HCT]15), ovarian (SKOV-3, OVCAR-3), leukemia (HL-60(TB), K-562), central nervous system (SF-268), renal (A498), osteosarcoma (U2-OS), and cervical (HeLa).
Inaddition, a mouse tumor line (B16, melanoma) was also growth-inhibited in the presence of the quinazolinone compounds.
A Gig was calculated by plotting the concentration of compound in pM vs the percentage of cell growth of cell growth in treated wells. The Gisq calculated for the compounds is the estimated concentration at which growth is inhibited by 50% 1S compared to contro, i.c., the concentration at which: 100 x {(Treatedss - To) / (Controle - To)] = 50.
All concentrations of compounds are tested in duplicate and controls are averaged over 12 wells. A very similar 96-well plate layout and Giso calculation scheme is used by the National Cancer Institute (see Monks, et al, J. Natl. Cancer Inst. 83:757-766 (1991)). However, the method by which the National Cancer Institute quantitates cell number does not use MTS, but instead employs altemative methods. :
Calculation Of ICs:
Measurement of a composition's ICs for KSP activity uses an ATPase assay. The following solutions are used: Solution 1 consists of 3 mM phosphoenolpyruvate potassium salt (Sigma P-7127), 2 mM ATP (Sigma A-3377), 1 mM IDTT (Sigma D- 9779), 5 uM paclitaxel (Sigma T-7402), 10 ppm antifoam 289 (Sigma A-8436), 25 mM Pipes/KOH pH 6.8 (Sigma P6757), 2 mM MgC12 (VWR JT400301), and 1 mM
EGTA (Sigma E3889). Solution 2 consists of 1 mM NADH (Sigma N8129), 0.2 mg/ml BSA (Sigma A7906), pyruvate kinase 7U/ml, L-lactate dehydrogenase 10 U/ml
2 a (Sigma P0294), 100 nM KSP motor domain, 50 pg/ml microtubules, 1 mM DTT (Sigma D9779), 5 uM paclitaxel (Sigma T-7402), 10 ppm antifoam 289 (Sigma A- 8436), 25 mM Pipes/KOH pH 6.8 (Sigma P6757), 2 mM MgC12 (VWR JT4003-01), and 1 mM EGTA (Sigma E3889). Serial dilutions (8-12 two-fold dilutions) of the : 5 composition are made in a 96-well microtiter plate (Corning Costar 3695) using
Solution 1. Following serial dilution each well has 50 pl of Solution 1. The reaction is started by adding 50 pl of solution 2 to each well. This may be done with a multichannel pipettor either manually or with automated liquid handling devices. The microtiter plate is then transferred to a microplate absorbance reader and multiple absorbance readings at 340 nm are taken for each well in a kinetic mode. The observed rate of change, which is proportional to the ATPase rate, is then plotted as a function of the compound concentration. For a standard ICsp determination the data acquired is fit by the following four parameter equation using a nonlinear fitting program (e.g, Grafit 4): y= — Re + Backgromd 1+
Where y is the observed rate and x the compound concentration.
The quinazolinone compounds inhibit growth in a variety of cell lines, including cell lines (MCF-7/ADR-RES, HCT 5) that express P-glycoprotein (also known as Multi- drug Resistance, or MDR"), which conveys resistance to other chemotherapeutic drugs, such as pacilitaxel, Therefore, the quinazolinones are anti-mitotics that inhibit cell proliferation, and are not subject to resistance by overexpression of MDR* by drug-resistant tumor lines.
Other compounds of this class were found to inhibit cell proliferation, although Glso values varied. Gls; values for the quinazolinone compotmds tested ranged from 200 nM to greater than the highest concentration tested. By this we mean that although most of the compounds that inhibited KSP activity biochemically did inhibit cell proliferation, for some, at the highest concentration tested (generally about 20 pM), cell growth was inhibited less than 50%. Many of the compounds have Gls
8 2 values less than 10 uM, and several have Glsg values loss than 1 pM. Anti- proliferative compounds that have been successfully applied in fhe clinic to treatment of cancer (cancer chemotherapeutics) have Glsy’s that vary greatly. For example, in
A549 cells, paclitaxel Gly is 4 nM, doxorubicin is 63 nM, 5-fluorouracil is 1 uM, and 5S hydroxyurea is 500 pM (data provided by National Cancer Institute, Developmental
Therapeutic Program, http://dtp.nci.nih.gov/). Therefore, compounds that inhibit cellular proliferation at virtually any concentration may be useful. However, preferably, compounds will have Gls values of less than 1 mM. More preferably, compounds will have Glsq values of less than 20 uM. Even more preferably, compounds will have Gly values of less than 10 pM. Further reduction in Glso values may also be desirable, including compounds with Glsy values of less than 1 pM.
Some of the quinazolinone compounds of the invention inhibit cell proliferation with
Glsg values from below 200 nM to below 10 nM.
Example 11
Female nude mice weighing approximately 20 g were implanted s.c. by trocar with fragments of human tumor carcinomas harvested from s.c. growing tumors in nude mice host. When the tumors were approximately 77 mg in size, the animals were pair matched into treatment and control groups. Each group cantainted 8 tumored mice, each of which was ear-tagged and followed individually throughout the experiment. Initial doses (10 mL/kg of a 66 mM Citrate buffer, pH 5.0 / 0.9% Saline / 10% Tween 80 formulation of each test compound having a maximum concentration of S mg/ml.) were given on Day 1 following pair matching, dosing at the levels and schedules indicated.
Mice were weighed twice weekly, and tumor measurements were taken by calipers twice weekly, starting on Day 1. These tumor measurements were converted to mg tumor weight by a well-known formula, W? x L/2. The experiment was terminated when the control group tumor size reached an average of 1 gram. Upon termination, the mice were weighted, sacrificed and their tumors excised. Tumors were weighted and the mean treated tumor weight per group was calculated. In this model, the change in mean treated tumor weight / the change in mean control tumor weight x 100% (AT/AC) was subtracted from 100% to give the tumor growth inhibition (TG) for each group.
Compounds 1-5 (below) were tested by the above-described method, giving the results summarized below in Tables A - D. Other compounds of the present invention show comparable activities when tested by this method.
Compound 1 “
Compound 2 ZL
Compound 3 . Compound 4 : :
Compound 5 2
= a
Table A
SKOV3 tumor xenograft :
Jon
Dose & Deilyx 5 80 mg/kg every 20 mg/kg
Schedule 3 daysx4 daily x 5
NF I I al I NL LI
Final Tumor | 904.1+126.5( 554.3176.8 90.4 + 36.0
Weight (Mean + SEM)
Tumor Growth 91.7%
Inhibition
Mice with
Partial Tumor
Shrinkage
Mean % 27.9%
Tumor }
Shrinkage
Maximum None 16.5%
Weight Loss wim 0 [Ur]
Table B
SKOV?3 tumor xenograft
IE SC cl Ki
Dose & Daily x 5 50 mg/kg every 60 mg/kg 20 mg/kg
Schedule 3daysx4 daily x 5 dailyx 5
Bc HC HN
Waal NN NL FL NL
Final Tumor 15063+227.1 | 34081930 | 806111638 | 55.9+294
Weight (Mean + SEM)
Tumor Growth 81.5% 48.3% 99.7%
Inhibition
Mice with 7
Partial Tumor
Shrinkage
Mean %
Tumor
Shrinkage
Maximum None 2.76% 7.49%
Weight Loss wii | 0 | ©] t ] °
Table C
SKOV3 tumor xenograft
I a
Dose & Daily x 5 4 mg/kg 20 mg/kg
Schedule weekly x 3 daily x § a IL
Fad IL I A
Final Tumor 1191.1 £239.6 | 726911472 | 90.6134.5
Weight (Mean i SEM)
Tumor Growth 40.1% 87.1%
Inhibition
Mice with
Partial Tumor ,
Shrinkage
Mean % 44.4%
Tumor
Shrinkage
Maximum 0.02% 12.26%
Weight Loss a SLI LI RL
Table D
SKOV3 tumor xenograft
I Me cid
Dose & Dailyx 5 25 mg/kg 20 mg/kg
Schedule : dailyx 5 dailyx 5 al EL
J cd I EA NL
Final Tumor 1230.4 £227.3 | 405.61124.8 | 379.0+154.0
Weight (Mean + SEM)
Tumor Growth 71.0% 73.0%
Inhibition
Mice with
Partial Tumor
Shrinkage
Mean %
Tumor
Shrinkage
Maximum 8.77% - | Weight Loss pots | 0 1° 1°]
While the present invention has been described with reference to the specific embodiments thereof, it should be understood by those skilled in the art that various changes may be made and equivalents may be substituted without departing from the true spirit and scope of the invention. In addition, many modifications may be made to adapt a particular situation, material, composition of matter, process, process step or steps, to the objective, spirit and scope of the present invention. All such modifications are intended to be within the scope of the claims appended hereto. All patents and publications cited above are hereby incorporated by reference.
Claims (64)
1. A compound for use in a method of treating cellular proliferative diseases comprising administering the compound which is chosen from the group consisting of: 0 Rs (o] Rs Ry Re R Re Nn RNY ; ow |] ow Ry’ XN Ry’ A N R; N R; lo} N Rs N Re hd Sg, d “Sr, Rs Ra- 0] Rs Ry Re 0 Rs Sy R, | Ry Rs Ry’ A pe N Ry R, Ry XN N R N R; iil SR, : N Rs Ry and nw Sg, wherein: R; is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, and substituted alkylheteroaryl; R; and R;’ are independently chosen from hydrogen, alkyl, oxaalkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, and substituted alkylheteroaryl; or R; and R;’ taken together form a 3- to 7-membered ring; R; 1s chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, substituted alkylheteroaryl, oxaalkyl, oxaalkylaryl, substituted oxaalkylaryl, oxaalkylheteroaryl, substituted oxaalkylheteroaryl, R;sO- and R;s-NH-; -58- AMENDED SHEET
Rj is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, substituted alkylheteroaryl, and R;s-NH-; Rj; is chosen from alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, and substituted alkylheteroaryl, Ry is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, substituted alkylheteroaryl, and R;¢-alkylene-; Rs, Rg, R7 and Rg are independently chosen from hydrogen, alkyl, alkoxy, halogen, fluoroalkyl, nitro, cyano, dialkylamino, alkylsulfonyl, alkylsulfonamido, sulfonamidoalkyl, sulfonamidoaryl, alkylthio, carboxyalkyl, carboxamido, aminocarbonyl, aryl and heteroaryl; Rs is chosen from alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, and substituted alkylheteroaryl; and Rie is chosen from alkoxy, amino, alkylamino, dialkylamino, N-heterocyclyl and substituted N-heterocyclyl, or a pharmaceutically acceptable salt thereof.
2. A compound for use in a method of treating a disorder associated with KSP kinesin activity comprising administering the compound which is chosen from the group consisting of: 0 Rs 0 Rs ow |] ol Ry’ RN Ry AN JA Ry JA Ry NT Rg on Re Ra Rar -59- AMENDED SHEET
0 Re aN Re 0 Re or | AN Re “JA . SE Ry! EY sor” Sr, ~ JA v
L and We ~ wherein:
R; is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl,
and substituted alkylheteroaryt;
R; and Ry’ are independently chosen from hydrogen, alkyl, oxaalkyl, aryl, alkylaryl, alkylaryl, substituted heteroaryl, and substituted alkylheteroaryl; or Ry and Ry’ taken together form a 3- to 7-membered ring;
Rg is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylhsteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, substituted alkyiheteroaryl, axaalkyl, axsalkylaryl, substituted oxaalkylaryl, oxaalkylheteroaryl, substituted oxaalkylheteroaryl, R1sO-and Rys-NH-;
Ry: is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl,
substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, substituted alkyiheteroaryl and Rys-NH-;
Rg~ is chosen from alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, and substituted alkyiheteroaryl;
: 20 Ry is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, substituted alkylheteroaryl, and Ris-alkylene-;
Rs, Ré, R7 and R are independently chosen from hydrogen, alkyl, alkoxy, halogen, flucroalkyl, itro, cyano, dialkylamino, alkylsulfonyl, alkylsulfonamido,
sulfonamidoalicyl, sulforumidoaryl, alkylthio, carboxyalkyl, carboxamido,
aminocarbonyl, aryl and heteroaryl; Ris is chosen from alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, and substituted alkylheteroaryl; and Ri is chosen from alkoxy, amino, alkylamino, dialkylamino, N-heterocyclyl and substituted N-heterocyclyl, or a pharmaceutically acceptable salt thereof.
3. A compound for use in a method of inhibiting KSP kinesin comprising contacting KSP kinesin with the compound which is chosen from the group consisting of:
[0] Rs Q Rs Ry Rs R Re NN ENE R, | R, R,' XN Ry’ NY N Ry N Ry lo} N Rg N Re hd Sg, d “Sg, Rs Ra 0 Rs R, Re 0] Rs Sy R; | Ry Re Ry Xn Sn N Ry R; Ry XN N R N R7 i Sg, ° N Rs Ra and vd SR, wherein: Rj is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, and substituted alkylheteroaryl; R; and R;’ are independently chosen from hydrogen, alkyl, oxaalkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted -61 - AMENDED SHEET alkylaryl, substituted heteroaryl, and substituted alkylheteroaryl; or R; and Ry’ taken together form a 3- to 7-membered ring;
R; is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl,
substituted alkylheteroaryl, oxaalkyl, oxaalkylaryl, substituted oxaalkylaryl, oxaalkylheteroaryl, substituted oxaalkylheteroaryl, RisO-and R;s-NH-;
Ry is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, substituted alkylheteroaryl and R;s-NH-;
Ry~ is chosen from alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, and substituted alkylheteroaryl;
Ry is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl,
substituted alkylheteroaryl, and Ris-alkylene-;
Rs, Re, Ry and Ry are independently chosen from hydrogen, alkyl, alkoxy, halogen, fluoroalkyl, nitro, cyano, dialkylamino, alkylsulforyl, alkylsulfonamido, sulfonamidoalkyl, sulfonamidoaryl, alkylthio, carboxyalkyl, carboxamido, aminocarbonyl, aryl and heteroaryl;
Ry; is chosen from alkyl, aryl, alky'aryl, heteroaryl, alkyiheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, and substituted alkylheteroaryl; and
Ry is chosen from alkoxy, amino, alkylamino, dialkylamino, N-heterocyclyl and substituted N-heterocyclyl,
ora pharmaceutically acceptable salt thereof.
4, A compound according to claim 1, 2 or 3 wherein: R, is chosen from hydrogen, alkyl, aryl, substituted alkyl, substituted aryl, heteroaryl, substituted heteroaryl, alkylaryl, substituted alkylaryl and substituted alkylheteroaryl; Rjis chosen from hydrogen, alkyl and substituted alkyl; R;’ is hydrogen; Ri is chosen from alkyl, substituted alkyl, alkylaryl, heteroaryl, aryl, substituted aryl, substituted hereroaryl, substituted oxaalkylaryl R;sO- and R,s-NH-; R4 is chosen from alkyl, aryl, alkylaryl, alkylheteroaryl, substituted alkyl, substituted aryl, and R,¢-alkylene-; Rs is hydrogen; Re, R7 and Rg are independently chosen from hydrogen, halogen, methyl, cyano and trifluoromethyl; Rs is chosen from alkyl, aryl and substituted aryl; Rye 1s chosen from alkoxy, amino, alkylamino, dialkylamino and N-heterocyclyl.
5. A compound according to claim 1, 2 or 3 wherein: R; is chosen from hydrogen, alkyl and substituted alkyl; R,’ is hydrogen; and the stereogenic center to which R; and R;’ are attached is of the R configuration.
6. A compound according to claim 1, 2 or 3 of the formula: 0} Rs mo] + N R; Ne Re Ra or a pharmaceutically acceptable salt thereof. -63- AMENDED SHEET
7. A compound according to claim 6 wherein R, is chosen from hydrogen, lower alkyl, substituted lower alkyl, aryl, substituted aryl, alkylaryl and substituted alkylaryl.
8. A compound according to claim 7 wherein R, is chosen from hydrogen, ethyl, propyl, methoxyethyl, naphthyl, phenyl, bromophenyl, chloropheny!, methoxyphenyl, ethoxyphenyl, tolyl, dimethylphenyl, chorofluorophenyl, methylchlorophenyl, ethylphenyl, phenethyl, benzyl, chlorobenzyl, methylbenzyl, methoxybenzyl, tetrahydrofuranylmethyl and (ethoxycarbonyl)ethyl.
9. A compound according to claim 6 wherein R; is chosen from hydrogen, lower alkyl and substituted lower alkyl; R;’ is hydrogen; and the stereogenic center to which R; and R;’ are attached is of the R configuration.
10. A compound according to claim 9 wherein R; is chosen from hydrogen, methyl, ethyl, propyl, methylthioethyl, aminobutyl, (CBZ)aminobutyl, cyclohexylmethyl, benzyloxymethyl, methylsulfinylethyl, methylsulfinylmethyl, hydroxymethyl, benzyl and indolylmethyl.
11. A compound according to claim 6 wherein Rj is chosen from C,;-C,; alkyl; substituted lower alkyl; aryl, substituted aryl, alkylaryl, alkylheteroaryl, oxaalkylaryl, oxaalkylheteroaryl, substituted alkylaryl, substituted alkylheteroaryl, substituted oxaalkylaryl, and substituted oxaalkylheteroarlyl.
12. A compound according to claim 11 wherein Rj is chosen from ethyl, propyl, chloropropyl, butoxy, heptyl, butyl, octyl, tridecanyl, (ethoxycarbonyl)ethyl, dimethylaminoethyl, dimethylaminomethyl, phenyl, naphthyl, halophenyl, dihalophenyl, cyanophenyl, halo(trifluoromethyl)phenyl, chlorophenoxymethyl, methoxyphenyl, carboxyphenyl, ethylphenyl, tolyl, biphenylyl, methylenedioxyphenyl, methylsulfonylphenyl, methoxychlorophenyl, chloronaphthyl, methylhalophenyl, trifluoromethylphenyl, butylphenyl, pentylphenyl, methylnitrophenyl, phenoxymethyi, dimethoxyphenyl, phenylvinyl, nitrochlorophenyl, nitrophenyl, dinitrophenyl, bis(trifluoromethyl)phenyl, benzyloxymethyl, benzyl, furanyl, benzofuranyl, pyridinyl, -64 - AMENDED SHEET indolyl, methylpyridinyl, quinolinyl, picolinyl, pyrazolyl, and imidazolyl.
13. A compound according to claim 6 wherein Rj is Rys-NH- and Rs is chosen from lower alkyl; cyclohexyl; phenyl; and phenyl substituted with halo, lower alkyl, loweralkoxy, or lower alkylthio.
14. A compound according to claim 13 wherein Rs is chosen from isopropyl, butyl, cyclohexyl, phenyl, bromophenyl, dichlorophenyl, methoxyphenyl, ethylphenyl, tolyl, trifluoromethylphenyl and methylthiophenyl.
15. A compound according to claim 6 wherein Ry is chosen from lower alkyl, substituted lower alkyl, cyclohexyl; phenyl substituted with hydroxy, lower alkoxy or lower alkyl; benzyl; heteroarylmethyl; heteroarylethyl; heteroarylpropyl and Rj¢-alkylene-, wherein R¢ is amino, lower alkylamino, di(lower alkyl)amino, lower alkoxy, or N-heterocyclyl.
16. A compound according to claim 15 wherein Ry is chosen from methyl, ethyl, propyl, butyl, cyclohexyl, carboxyethyl, carboxymethyl, methoxyethyl, hydroxyethyl, hydroxypropyl, dimethylaminoethyl, dimethylaminopropyl, diethylaminoethyl, diethylaminopropyl, aminopropyl, methylaminopropyl, 2,2- dimethyl-3-(dimethylamino)propyl, 1-cyclohexyl-4-(diethylamino)butyl, aminoethyl, aminobutyl, aminopentyl, aminohexyl, aminoethoxyethyl, isopropylaminopropyl, diisopropylaminoethyl, 1-methyl-4-(diethylamino)butyl, (t-Boc)aminopropyl, hydroxyphenyl, benzyl, methoxyphenyl, methylmethoxyphenyl, dimethylphenyl, tolyl, ethylphenyl, (oxopyrrolidinyl)propyl, (methoxycarbonyl)ethyl, benzylpiperidinyl, pyridinylethyl, pyridinylmethyl, morpholinylethyl, morpholinylpropyl, piperidinyl, azetidinylmethyl, azetidinylpropyl, pyrrolidinylethyl, pyrrolidinylpropyl, piperidinylmethyl, piperidinylethyl, imidazolylpropyl, imidazolylethyl, (ethylpyrrolidinyl)methyl, (methylpyrrolidinyl)ethyl, (methylpiperidinyl)propyl, (methylpiperazinyl)propyl, furanylmethyl and indolylethyl. -65 - AMENDED SHEET
17. A compound according to claim 6 wherein R, is chosen from lower alkyl, benzyl, substituted benzyl and substituted phenyl; R; is chosen from hydrogen, alkyl, substituted lower alkyl and benzyl; R;’ is hydrogen; Rjis chosen from substituted phenyl and naphthyl; R4 is chosen from substituted alkyl and R¢-alkylene-; Rs is hydrogen or halo Rs is hydrogen, methyl or halo; R7 is hydrogen, halo, lower alkyl, substituted lower alkyl, lower alkoxy or cyano; Rgis hydrogen or halo; and Ri¢ is chosen from di(lower alkylamino), (lower alkyl)amino, amino, N-heterocyclyl and substituted N-heterocyclyl.
18. A compound according to claim 1, 2 or 3 wherein Ris benzyl or halobenzyl, R; is chosen from ethyl and propyl; R;’ is hydrogen, Rj is substituted phenyl; R3: is substituted phenyl; Rs is substituted phenyl; Rs is -(CH2)mOH or -(CH;)pRi6 wherein mis 2 or 3 and p is 1-3; Rs is hydrogen; Rg is hydrogen; R; is halo; Rgis hydrogen; and Ri¢ 1s chosen from amino, propylamino, and azetidinyl.
19. A compound according to claim 18 wherein the stereogenic center to which R; and R;: are attached is of the R configuration. - 66 - AMENDED SHEET
20. A compound according to claim 1, 2 or 3 of the formula: 0 Rs Ry Re Sy Rr; R,' XN N R; N Rs i Sg, Ry or a pharmaceutically acceptable salt thereof.
21. A compound according to claim 20 wherein: Rj is chosen from hydrogen, lower alkyl, substituted lower alkyl, benzyl, substituted benzyl, phenyl, naphthyl and substituted phenyl; R; is chosen from hydrogen, lower alkyl and substituted lower alkyl and R;’ is hydrogen; R3- 1s chosen from C,-C,; alkyl; phenyl; naphthyl; phenyl substituted with halo, lower alkyl, lower alkoxy, nitro, methylenedioxy, or trifluoromethyl; biphenylyl, benzyl and heteroaryl; and R4 1s chosen from lower alkyl, substituted lower alkyl, cyclohexyl; phenyl substituted with hydroxy, lower alkoxy or lower alkyl; benzyl; heteroarylmethyl, heteroarylethyl; heteroarylpropyl and R¢-alkylene, wherein Rye is amino, (lower alkyl)amino, di(lower alkyl)amino, lower alkoxy, or N- heterocyclyl.
22. A compound according to claim 20 wherein
R. is chosen from lower alkyl, benzyl, substituted benzyl and substituted phenyl; R; is hydrogen or lower alkyl; Ry’ is hydrogen; Rj: is chosen from substituted phenyl and naphthyl, Rs 1s Ryg-alkylene-, hydroxy lower alkyl or carboxy lower alkyl; Re and R; are chosen from hydrogen and halo; -67 - AMENDED SHEET
Rs and Rg are hydrogen; Ris is chosen from di(lower alkylamino), (lower alkyl)amino, amino, piperidinyl, azetidinyl pyrrolidinyl and morpholinyl.
23. A compound according to claim 1, 2 or 3 of the formula: lo) Rs Ri Re SN ow |] RJ’ NW N R; N Rs rd SR, or a pharmaceutically acceptable salt thereof.
24. A compound according to claim 23 wherein: R; is chosen from hydrogen, lower alkyl, substituted lower alkyl, benzyl, substituted benzyl, phenyl, naphthyl and substituted phenyl; Rj is chosen from hydrogen, lower alkyl and substituted lower alkyl and R;’ is hydrogen; and Ry is chosen from lower alkyl, cyclohexyl; phenyl substituted with hydroxy, lower alkoxy or lower alkyl; benzyl; heteroarylmethyl; heteroarylethyl; heteroarylpropyl and R¢-alkylene, wherein R)¢ is di(lower alkyl)amino, alkylamino, amino, lower alkoxy, or N-heterocyclyl.
25. A compound according to claim 23 wherein R, is chosen from lower alkyl, benzyl, substituted benzyl and substituted phenyl; R; is hydrogen or lower alkyl, R,’ is hydrogen; Ris Ryg-alkylene-; Re and R; are chosen from hydrogen and halo; - 68 - AMENDED SHEET
Rs and Rg are hydrogen; and Rie is chosen from di(lower alkylamino), (lower alkyl)amino, amino, pyrrolidinyl, piperidinyl, imidazolyl and morpholinyl.
26. A compound according to claim 1, 2 or 3 of the formula: 0 Rs Ry Re Sy R, Ry AN N Ry N Re [ Ry or a pharmaceutically acceptable salt thereof.
27. A compound according to claim 26 wherein: R| is chosen from hydrogen, lower alkyl, substituted lower alkyl, benzyl, substituted benzyl, phenyl, naphthyl and substituted phenyl; Rj is chosen from hydrogen, lower alkyl and substituted lower alkyl and R;’ is hydrogen; R; 1s chosen from C,-C,; alkyl; substituted lower alkyl; phenyl; naphthyl; phenyl substituted with halo, lower alkyl, lower alkoxy, nitro, methylenedioxy, or trifluoromethyl; biphenylyl; benzyl and heterocyclyl; and Rysis chosen from lower alkyl, substituted lower alkyl; cyclohexyl; phenyl substituted with hydroxy, lower alkoxy or lower alkyl; benzyl; substituted benzyl; heterocyclyl; heteroarylmethyl; heteroarylethyl; heteroarylpropyl and Rie- alkylene, wherein Re is di(lower alkyl)amino, (lower alkyl)amino, amino, lower alkoxy, or N- heterocyclyl. -69 - AMENDED SHEET
28. A compound according to claim 27 wherein R, is chosen from lower alkyl, benzyl, substituted benzyl and substituted phenyl; R; is hydrogen or lower alkyl; R;’ is hydrogen; Rj is chosen from substituted phenyl, heterocyclyl and naphthyl; Rs 1s chosen from subtituted benzyl, heterocyclyl substituted lower alkyl and R¢- alkylene-; Re and Ry are chosen from hydrogen and halo; Rs and Rg are hydrogen; Rye 1s chosen from di(lower alkylamino), (lower alkyl)amino, amino, pyrrolidinyl, azetidinyl piperidinyl, imidazolyl and morpholinyl.
29. A compound according to claim 28 wherein R; is benzyl, R; is ethyl; Rj’ is hydrogen; R;- is chosen from halophenyl, polyhalophenyl, tolyl, dimethylphenyl, methoxyphenyl, dimethoxyphenyl, cyanophenyl, trifluoromethylphenyl, trifluoromethoxyphenyl, bis(trifluoromethyl)phenyl, carboxyphenyl, t-butylphenyl, methoxycarbonylphenyl, piperidinyl and naphthyl, Rais chosen from substituted benzyl, piperidinyl, hydroxy (lower alkyl) and R- alkylene-; R¢ and R; are chosen from hydrogen and halo; Rs and Rg are hydrogen; Ri¢ 1s chosen from dimethylamino, amino, pyrrolidinyl and piperidinyl.
30. A compound according to claim 1 or 2 wherein said disease or disorder is chosen from the group consisting of cancer, hyperplasia, restenosis, and cardiac hypertrophy. -70 - AMENDED SHEET
31. A compound chosen from the group consisting of: fo) Rs 0 Rs Ry 1 Sn h MN . Fe JA | JA Re’ A Ry’ Ax N Ry N Ry 0 N Re N Re J a and Re wherein:
R is chosen from hydrogen, alkyl, alkylaryl, alkylheteroaryl, substituted alkyl, substituted alkylaryl, and substituted alkylhetexoaryl;
Ry and R;’ are independently chosen from hydrogen, alkyl, oxaalkyl, aryl, alkylaryl,
alkylaryl, substituted heteroaryl, and substituted alkylheteroaryl; or Ry and Ry’ taken together form a 3- to 7-membered ring;
R; is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, substituted alkylheteroaryl, oxaalkyl, oxaalkylaryl, substituted oxsalkylaryl,
oxaalkyliheteroaryl, substituted oxaalkyfheteroaryl, RisO- and R;s-NH-;
Rs~ is chosen from alkyl, aryl, alkylaryl, heteroaryl, alkytheteroaryl, substituted alkyl, alkylheteroaryl;
Ry is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl,
substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, substituted alkylheteroaryl, and Ris-alkylene-;
Rs, Rg, Ry and Rg are independently chosen from hydrogen, alkyl, alkoxy, halogen, fluoroalkyl, nitro, cyano, dialkylamino, alkylsulfonyl, alkcylsulfonamido, sulfonamidoalkyl, sulfonamidoaryl, alkylthio, carboxyalkyl, carboxamido,
aminocarbonyl, aryl and heteroaryl; Rus is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkytheteroaryl,
substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, and substituted alkyTheteroaryl; and a. Ris is chosen from alkoxy, amino, alkylamino, dialkylamino, N-heterocyclyl and substituted N-heterocyclyl, or apharmaceutically acceptable salt thereof, with the proviso that when Rj; is R;s-NH-, both of R; and R, must be other than hydrogen.
32. A compound chosen from the group consisting of: © 0 Re Rin Re 0 Re N Ra Ry Re Ll ~ N Ry Ra Ry" Nn il Re N Ry N Re wi HOR wherein: . R, is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkyiheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, and substituted alkylheteroaryl; R; and R;’ are independently chosen from hydrogen, alkyl, axaalkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, and substituted alkylheteroaryl; or R; and R,’ taken together form a 3- to 7-membered ring; Ry is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkyiheteroaryl, substituted alkylheteroaryl and R;s-NH-; Ry is chosen from hydrogen, alkyl, aryl, alkylary), heteroaryl, alkylheteroary), substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, substituted alkylheteroaryl, and R,¢-alkylene-;
. -T-
= GS Rs, Rg, Ry and Ry are independently chosen from hydrogen, alkyl, alkoxy, halogen, fluoroalkyl, nitro, cyano, dialkylamino, alkyisulfonyl, alkylsuifonamido, sulfonamidoalkyl, sulfonamidoaryl, alkylthio, carboxyalkyl, carboxamido, aminocarbonyl, aryl and heteroaryl; Rysis chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, and substituted alkylheteroaryl; and Ry¢ is chosen from alkoxy, amino, alkylamino, dialkylamino, N-heterocyclyl and substituted N-heterocyclyl, ora phannaceutically acceptable salt thereof.
33. A compound or salt according to claim 31 or 32 wherein: R; is chosen from hydrogen, alkyl, aryl, substituted alkyl, substituted aryl, heteroaryl, R; is chosen from hydrogen, alkyl and substituted alkyl; R,’ is hydrogen; and the : 15 stereogenic center to which R; and Ry’ are attached is of the R configuration. R; is chosen from alkyl, aryl, alkylaryl, heteroaryl, substituted aryl, substituted alkyl, substituted heteroaryl, oxaalkylaryl, substituted oxaalkylaryl, RisO- and Rys- NH-; . Ry is chosen from alkyl, aryl, alkylaryl, alkylheteroaryl, substituted alkyl, substituted aryl, and Ric-alkylene-; Rs is rydrogen, Re R7 and Ry are independently chosen from hydrogen, halogen, methyl and Rs is chosen from alkyl, aryl and substituted aryl; and Ry is chosen from alkoxy, amino, alkylamino, dialkylamino and N-heterocyclyl.
34. A compound according to claim 31 of formula: 0 Re . R Re "NN JA Ry" x N Ry 0) N J or a pharmaceutically acceptable salt thereof.
35. A compound or salt according to claim 34 wherein R, is chosen from hydrogen, lower alkyl, substituted lower alkyl, alkylaryl or substituted alkylaryl.
36. A compound or salt according to claim 35 wherein R; is chosen from hydrogen, ethyl, propyl, methoxyethyl, phenethyl, benzyl, chiorobenzyl, methylbenzyl, - methoxybenzyl, tetrahydrofuranyimethyl and (ethoxycarbonyl)ethyl.
37. A compound or salt according to claim 34 wherein R; is chosen from hydrogen, lower alkyl and substituted lower alkyl; Ra’ is hydrogen.; and the stereogenic center to which Ry and R,’ are attached is of the R configuration.
38. A compound or salt according to claim 37 wherein R; is chosen from ethyl, i-propyl, c-propyl or t-butyl.
39. A compound or salt according to claim 34 or 37 wherein R; is chosen from aryl, substituted aryl, alkylaryl, alkylheteroaryl, oxaalkylaryl, oxaalkylheteroaryl, substituted alkylaryl, substituted alkylheteroaryl, substituted oxaalkylaryl or substituted oxaalkyiheteroaryl.
40. A compound or salt according to claim 39 wherein Rj is chosen from phenyl, substituted phenyl, benzyl, substituted benzyl, phenylvinyl, substituted phenylvinyl, phenoxy lower alkyl and substituted phenoxy lower alkyl, furanyl, * benzofuranyl, pyridinyl, indolyl, methylpyridinyl, quinolinyl, picolinyl, pyrazolyl, and imidazolyl.
41. A compound or salt according to claim 40 wherein R; is chosen from halophenyl, dihalophenyl, cyanophenyl, halo(trifluoromethyl)phenyl, chlorophenoxymethyl, methoxyphenyl, carboxyphenyl, methyiphenyl, ethylphenyl, tolyl, biphenylyl, methylenedioxyphenyl, methylsulfonylphenyl, methoxychlorophenyl, methylhalophenyl, trifluoromethylphenyl, butylphenyl, pentylphenyl, methylnitrophenyl, dimethoxyphenyl, phenylvinyl, nitrochlorophenyl, : nitrophenyl, dinitrophenyl, bis(trifluoromethyl)phenyl,
42. A compound or salt according to claim 37 wherein R; is R;s-NH- where Rs is chosen from isopropyl, butyl, cyclohexyl, phenyl, bromophenyl, dichlorophenyl, methoxyphenyl, ethylphenyl, tolyl, trifluoromethyiphenyl and. methyithiophenyl.
43. A compound or salt according to claim 34, 37 or 39 wherein R, is chosen from lower alkyl, substituted lower alkyl, and Ri¢-alkylene-, wherein R¢ is amino, lower alkylamino, di(lower alkyl)amino, lower alkoxy, or N-heterocyclyl.
44, A compound or salt according to claim 34, 37 or 39 wherein Rs, Rg, Rs and Ry are chosen from hydrogen, halo, lower alkyl, substituted lower alkyl, lower alkoxy and cyano.
45. A compound or salt according to claim 44 wherein Rs, Rg and Ry are hydrogen.
46. A compound or salt according to claim 45 wherein R is halo.
CB
47. A compound or salt according to claim 34 wherein: R; is chosen from alkylaryl or substituted alkylaryl; Rq is lower alkyl; Ry’ is hydrogen; and the stereogenic center to which Rp and Ry’ are attached is of the R configuration; Ris substituted aryl; R4 is substituted alkyl; Rg is hydrogen; Rg is hydrogen; R; is halo or cyano; and Rgis hydrogen. }
48. The compound or salt according to claim 47 wherein: R; is benzyl or substituted benzyl; Rg is i-propyl; Rj is methyl- and/or halo-substituted phemyl; ' R, is 3-amino-n-propyl, Rs is hydrogen; Rg is hydrogen; Ry is chloro or cyano; and Ryis hydrogen.
49. The compound or salt according to claim 47 wherein: R, is benzyl; R; is i-propyl; Ris p-fluorophenyl; Ry is 3-amino-n-propyl; Rs is hydrogen; Rg is hydrogen, Rj is fluoro; and Rgis hydrogen.
MN ED
50. The compound or salt according to claim 47 wherein: R, is benzyl; R; is i-propyl; R; is p-fluorophenyl; Ry is 3-amino-n-propyl; Rs is hydrogen; Rg is hydrogen, Ry is chloro; and Ry is hydrogen.
51. The compound or salt according to claim 47 wherein: R; is benzyl, R, is i-propyl, Rg is 3-fluoro-4-methylphenyl; Rqis 3-amino-n-propyl; Rs is hydrogen; Rg is hydrogen; Ry is chloro; and Ryis hydrogen.
52. The compound or salt according to claim 47 wherein: R; is benzyl; R; is i-propyl; Ry is p-methylphenyl; Ris 3-amino-n-propyl; Ry is hydrogen; Rg is lrydrogen; Ris chloro; and Ryis hydrogen.
53. The compound or salt according to claim 47 wherein: R, is benzyl; R; is i-propyl; R; is p-methylphenyl; S Ry is 3-amino-n-propyl; Rs is hydrogen; Rg is hydrogen; R9 is cyano; and . . Rgishydrogen.
54. A compound according to claim 32 of formula: : 0 0) Rin Re JO Re! x . N Ry il Re or a pharmaceutically acceptable salt thereof.
55. A compound according to claim 54 wherein: 1S R, is chosen from hydrogen, lower alkyl, substituted lower alkyl, benzyl, substituted benzyl, phenyl, naphthyl and substituted phenyl; R; is chosen from hydrogen, lower alkyl and substituted lower alkyl and R;’ is hydrogen; Ry: is chosen from C;~Cy3 alkyl; phenyl; naphthyl; phenyl substituted with halo, lower alkyl, lower alkoxy, nitro, methylenedioxy, or triftuoromethyl; biphenylyl, benzyl and heteroaryl; and R, is chosen from lower alkyl, substituted lower alkyl, cyclohexyl; phemyl substituted with hydroxy, lower alkoxy or lower alkyl, benzyl; heteroarylmethyl; heteroarylethyl; heteroarylpropyl and Rie-alkylene, wherein Ry is amino, (lower alkyljamino, di(lower alkyDamino, lower alkoxy, or N- heterocyclyl.
56. A compound according to claim 55 wherein: Ry is chosen from lower alkyl, benzyl, substituted benzyl and substituted phenyl, R; is hydrogen or lower alkyl; Ry’ is hydrogen; Ris chosen from substituted phenyl and naphthyl; Ru is Ry-alkylene-, hydroxy(lower alkyl) or carboxy (lower alkyl); Rj is hydrogen, fluoro, chloto or methyl; Rs, Rg and Rg are hydrogen, Ry is chosen from di(lower alkyl)amino, (lower alkyl)amino, amino, pyrrolidinyl and piperidinyl.
57. A compound according to claim 32 of formula: 1% 5] Ry Re Ny JA Re! xX N Ry N Re Ww “Sr, or a pharmaceutically acceptable salt thereof.
58. A compound ar salt according to claim 57 wherein: R, is chosen from hydrogen, lower alkyl, substituted lower alkyl, benzyl, substituted benzyl, phenyl, naphthyl and substituted phenyl; R; is chosen from hydrogen, lower alkyl and substituted lower alkyl and R,’ is hydrogen; and R, is chosen from lower alkyl, cyclohexyl; phenyl substituted with hydroxy, lower alkoxy or lower alkyl; benzyl; hoteroaryimethyl; heteroaryiethyl; heteroarylpropyl and Re-alkylene, wherein Rye is dilower alkyl)amino, (lower alkyl)amino, amino, lower alkaxy, or N-heterocyclyl.
& 0
59. A compound or salt according to claim 58 wherein: R, is chosen from lower alkyl, benzyl, substituted benzyl and substituted phenyl; Rj is hydrogen or lower alkyl; Ry’ is hydrogen; - RsisRjealkylene-; Rj is hydrogen, fluoro, chloro or methyl; Rs, Rs and Rg are hydrogen; Ris is chosen from di(lower alkylamino), (lower alkyl)amino, amino, pyrrolidinyl, piperidinyl, imidazolyl and morpholinyl.
60. A compound according to claim 31 of formula: 0 Re Ris, Re “ N Ry ~ Re or a pharmaceutically acceptable salt thereof.
61. A compound or salt according to claim 60 wherein: R is chosen from hydrogen, lower alkyl, substituted lower alkyl, alkylaryl or substituted alkylaryl; Rg is chosen from hydrogen, lower alkyl and substituted lower alkyl; Ry’ is hydrogen; and the stereogenic center to which Ra and R;’ are attached is of the R configuration; Ry» is chosen from aryl, substituted aryl, alkylaryl, alkylheteroaryl, oxaalkylaryl, oxaalkyiheteroaryl, substituted alkylaryl, substituted alkytheteroaryl, substituted oxaalkylaryl or substituted oxaalkylheteroaryl; and Ry is chosen from lower alkyl, substituted lower alkyl, and R,e-alkylene, wherein Rys is di(lower alkyl)amino, (lower alkyl)amino, amino, lower alkoxy, or N- heterocyclyl.
62. A compound substantially as herein described with reference to Figure
63. A method of screening for KSP kinesin modulators comprising: (a) combining a kinesin, a candidate bioactive agent and a compound chosen from the group consisting of: 0] Rs o] Rs R, Re R Re Ny NY R, | R, R,' AN Ry’ Nn N R; N R; (0) N Rg N Rg hd aS d Sg, Ra Rs 0 Rs R, Re 0 Rs Sn Rs | R; Re Ry’ Xe pa N Ry R, Ry’ NN N R N Ry iil SR, : N Rs Ry and nw Sg, wherein: Rj is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, and substituted alkylheteroaryl, R; and R;’ are independently chosen from hydrogen, alkyl, oxaalkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, and substituted alkylheteroaryl; or R; and R,’ taken together form a 3- to 7-membered ring; Rj; is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, -81 - AMENDED SHEET substituted alkylheteroaryl, oxaalkyl, oxaalkylaryl, substituted oxaalkylaryl, oxaalkylheteroaryl, substituted oxaalkylheteroaryl, RisO- and Ris-NH-;
Ry is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl,
substituted alkylheteroaryl and Rys-NH-;
Ryn is chosen from alkyl, aryl, alkylaryl, heteroaryl, alkcylheteroaryl, substituted alkyl, . substituted aryl, substituted alkylaryl, substituted heteroaryl, and substituted alkylheteroaryl;
Ru is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl,
substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, substituted alkylheteroaryl, and Rig-alkylene-; .
Rs, Re, Ry and Ry sre independently chosen from hydrogen, alkyl, alkoxy, halogen, fluoroalkyl, nitro, cyano, dialkylamino, alkylsulfonyl, alkylsulfonamido, sulfonamidoalkyl, sulfonamidoaryl, alkylthio, carboxyalkyl, carboxamido,
aminocarbomnyl, aryl and heteroaryl;
Ris is chosen from hydrogen, alkyl, aryl, alkylaryl, beteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, and substituted alkylheteroaryl; and
Rg is chosen from alkoxy, amino, alkylamino, dialkylamino, N-heterocyclyl and substituted N-heterocyclyl; and (b) determining the effect of said candidate bioactive agent on the activity of said kinesin.
64. A method of screening for compounds that bind to KSP kinesin comprising: (8) combining a kinesin, a candidate bioactive agent and a labeled compound chosen from the group consisting of: 0 Rs 0 Re R Re R Re Ny AN Ra Ra Re" x Re’ x N Ry N Ry 0 NG. . Ry N he NR, d NR, Re 0 Rs ANY Re 0 Re Ry Re Ry Ry! A Sy . wl Re’ x N N Ry iil NR, Re Re ad wo Sr,
wherein:
R, is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkyiheteroaryl,
substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, and substituted alkylheteroaryl,
Ra and Ry’ are independently chosen from hydrogen, alkyl, oxaalkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, and substituted alkylheteroaryl; orR; and Ry’
taken together form a 3- to 7-membered ring;
R, is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkyiheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, substituted alkylheteroaryl, oxaalkyl, oxaalkylaryl, substituted oxaalkylaryl, oxaalkylheteroaryl, substituted oxaalkyiheteroaryl, RysO- and R;s-NH-;
2 2
Ry is chosen from hydrogen, alkyl, ary}, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, substituted alkylheteroaryl and R;s-NH-;
Rj is chosen from alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryi, substituted alkyl,
S substituted aryl, substituted alkylaryl, substituted heteroaryl, and substituted alkylheteroaryl;
Ry is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, } substituted alkylheteroaryl, and Rs-alkylene-;
Rs, Re, R; and Ry are independently chosen from hydrogen, alkyl, alkoxy, halogen, flucroalkyl, nitro, cyano, dialkylamino, alkylsulfonyl, alkylsulfonamido, . sulfonamidoalkyl, sulfonamidoaryl, alkylthio, carboxyalkyl, carboxamido,
aminocarbonyl, aryl and heteroaryl;
Ris is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl,
substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, and substituted alkylheteroary}; and
Rye is chosen from alkoxy, amino, alkylamino, dialkylamino, N-heterocyclyl and "substituted N-heterocyclyl; and (b) determining the binding of said candidate bioactive agent to : said kinesin.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21310400P | 2000-06-21 | 2000-06-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200210133B true ZA200210133B (en) | 2003-06-17 |
Family
ID=30443702
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200210133A ZA200210133B (en) | 2000-06-21 | 2002-12-13 | Methods and compositions utilizing quinazolinones. |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN1824656A (en) |
ZA (1) | ZA200210133B (en) |
-
2001
- 2001-04-27 CN CN 200510119288 patent/CN1824656A/en active Pending
-
2002
- 2002-12-13 ZA ZA200210133A patent/ZA200210133B/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN1824656A (en) | 2006-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU774748B2 (en) | Methods and compositions utilizing quinazolinones | |
US6630479B1 (en) | Methods and compositions utilizing quinazolinones | |
US8658656B2 (en) | Methods and compositions utilizing quinazolinones | |
US8008311B2 (en) | Methods and compostions utilizing quinazolinones | |
AU2001259270A1 (en) | Methods and compositions utilizing quinazolinones | |
ZA200210133B (en) | Methods and compositions utilizing quinazolinones. |